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Summary 
Oncogenic human papillomavirus (HPV) types are major human carcinogens. Sustained 
expression of the viral E6 and E7 oncogenes is essential for the malignant growth of 
HPV-positive cancer cells. Moreover, cancer cells typically exhibit metabolic alterations. 
Surprisingly little is known about the relation between the HPV oncogenes and the cellular 
iron metabolism although it is increasingly recognised to be linked to tumourigenesis. Thus, 
the overall aim of the presented studies was to investigate the crosstalk between oncogenic 
HPVs and the iron metabolism of their tumourigenic host cells.  
Interestingly, treatment of HPV-positive cervical cancer cells with the iron chelators 
deferoxamine (DFO) or ciclopirox (CPX) strongly suppresses expression of the viral E6/E7 
oncogenes, suggesting therapeutic potential for these agents. Further detailed work was 
focused on CPX since (in contrast to DFO) this drug can be applied topically and thus could 
be suitable for the treatment of HPV-induced (pre)neoplasias. It was found that CPX 
efficiently blocks cellular proliferation in both 2D and 3D cell culture, induces cell cycle 
arrest in the G1 and S phase and ultimately leads to cellular senescence. Both E6/E7 
repression and senescence are a consequence of iron deprivation since they can be prevented 
by excess iron. Notably, although mTORC1 signalling is widely believed to be required for 
senescence induction, the pro-senescent activity of CPX is independent of mTORC1 
signalling. Proteome analyses revealed candidate proteins which might be involved in the 
CPX-induced growth arrest and senescence. Moreover, prolonged treatment of HPV-positive 
cervical cancer cells with CPX results in apoptosis which is observable under both normoxic 
and hypoxic conditions. Since CPX exerts pro-apoptotic effects also under hypoxia, it could 
be used in combination with radio- and chemotherapy which both are typically less active 
against hypoxic tumour cells. 
Taken together, these results reveal that HPV oncogene expression is very sensitive to iron 
deprivation. CPX could be a particularly promising agent for the treatment of HPV-positive 
cancers since it represses E6/E7, induces senescence and apoptosis under normoxic conditions 
and can also eliminate hypoxic cells which pose a major problem for the efficacy of 
anti-cancer drugs in the clinic.  
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Zusammenfassung 
Onkogene Typen humaner Papillomviren (HPVs) sind Hauptkarzinogene für den Menschen. 
Die kontinuierliche Expression der viralen E6- und E7-Onkogene ist essentiell für das 
maligne Wachstum HPV-positiver Tumore. Krebszellen besitzen zudem typischerweise 
metabolische Veränderungen. Überraschend wenig ist über eine mögliche Verbindung 
zwischen den HPV-Onkogenen und dem zellulären Eisenmetabolismus bekannt, obwohl 
dieser zunehmend mit der Krebsentstehung in Verbindung gebracht wird. Als übergeordnetes 
Ziel untersuchte die vorliegende Arbeit daher die Interaktion zwischen onkogenen HPVs und 
dem Eisenmetabolismus ihrer tumorigenen Wirtszellen. 
Interessanterweise führt die Behandlung HPV-positiver Zervixkarzinomzellen mit den 
Eisenchelatoren Deferoxamin (DFO) oder Ciclopirox (CPX) zu einer starken Hemmung der 
viralen E6/E7-Onkogenexpression, was auf ein therapeutisches Potenzial für diese 
angewandten Wirkstoffe hinweist. Weitere, detaillierte Untersuchungen waren auf CPX 
fokussiert, da dieses Medikament (im Gegensatz zu DFO) topisch angewandt werden kann 
und daher für die Behandlung HPV-induzierter (Prä-)neoplasien geeignet sein könnte. Es 
konnte gezeigt werden, dass CPX das Zellwachstum unter 2D- und 3D-
Zellkulturbedingungen effizient hemmt, die Zellen in der G1- und S-Phase arretiert und 
letztendlich zu zellulärer Seneszenz führt. Sowohl die E6/E7-Hemmung als auch die 
Seneszenz werden durch Eisenentzug verursacht, da sie durch einen Überschuss an Eisen 
verhindert werden können. Obwohl im Allgemeinen angenommen wird, dass ein aktiver 
mTORC1-Signalweg für die Seneszenz-Induktion notwendig ist, kann gezeigt werden, dass 
die pro-seneszente Wirkung von CPX unabhängig von mTORC1 erfolgt. Proteomanalysen 
ergaben Hinweise auf Proteine, die im Wachstumsarrestes und der Seneszenz durch CPX 
beteiligt sein könnten. Des Weiteren wird gezeigt, dass eine länger andauernde Behandlung 
mit CPX in HPV-positiven Zervixkarzinomzellen sowohl unter normoxischen als auch unter 
hypoxischen Bedingungen in Apoptose resultiert. Da CPX auch unter Hypoxie 
pro-apoptotisch wirkt, könnte CPX in Kombination mit Radio- und Chemotherapie eingesetzt 
werden, welche gegen hypoxische Zellen typischerweise weniger wirksam sind. 
Zusammenfassend zeigen die Ergebnisse, dass die HPV-Onkogenexpression sehr sensitiv auf 
Eisenentzug reagiert. CPX könnte ein besonders vielversprechender Wirkstoff für die 
Behandlung HPV-positiver Tumore sein, da es E6/E7 reprimiert, Seneszenz und Apoptose 
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unter normoxischen Bedingungen induziert und außerdem hypoxische Zellen eliminiert, die 
ein großes Problem für die Effizienz der Krebstherapie in der Klinik darstellen.   
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Introduction 
1. Introduction 
1.1 Human Papillomavirus (HPV) and cancer 
Human papillomaviruses (HPVs) are non-enveloped, double-stranded DNA viruses belonging 
to the family of papillomaviridae. More than 180 different HPV types are known [1]. 
Depending on their potential to induce cancer, HPVs can be grouped into high-risk and 
low-risk HPVs. Mucosal infection with low-risk HPVs (e.g. type 6 and 11) can cause benign 
genital warts and condylomas whereas lesions infected with high-risk HPVs (type 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58 and 59) may progress to cancer [2]. The causal role of HPV in 
carcinogenesis is best described in cervical cancer [3]. In the 19
th
 century, the Italian 
physician Rigoni-Stern noticed a high frequency of cervical cancer in married women, 
widows and prostitutes, whereas virgins and nuns very rarely showed signs of it; concluding 
that the incidence of this cancer is linked to sexual contact [4]. In the 1970s, zur Hausen and 
co-workers proposed that cervical cancer could be associated with HPV infection [5] and in 
1983, Dürst et al. were able to isolate HPV16 DNA from a cervical cancer specimen [6]. 
Today, it is known that virtually all cervical cancers are HPV-positive with the high-risk types 
HPV16 and HPV18 accounting for approximately 70% of all cases [7]. HPV16 alone causes 
40-60% of all cervical cancers [8]. In total, 4.5% of all human cancers worldwide are 
associated with HPV infections, among them are additional cancers of the anogenital region 
(vulva, vagina, penis, anus), head and neck cancers [9] and non-melanoma skin cancer [10]. 
Because of the important role of high-risk HPV types as human carcinogens, prophylactic 
vaccines have been developed. Gardasil®9 is a nonavalent vaccine which protects against 
HPV6, 11, 16, 18, 21, 33, 45, 52 and 58 and thus against 90% of all cervical cancer cases in 
women and 80-95% of other HPV-related cancers in both men and women [11]. However, 
despite the efficiency and success of these vaccines, only 1.7% of all females worldwide 
received at least one shot of HPV vaccines with developing countries having the lowest 
vaccination rates [12]. Thus, cervical cancer will remain a major health care problem in the 
future.  
1.2 Pathogenesis of HPV-linked cancer 
HPVs infect keratinocytes in the basal layer of squamous epithelia, i.e. skin and mucosal 
surfaces, and their replication is tightly linked to the host cell’s differentiation status [13]. 
During cell division, keratinocytes differentiate and progress to the surface of the epithelium 
where the viral particles can be released. Infections with HPV types are often cleared by the 
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immune system without manifestation of clinical symptoms [14]. However, if oncogenic HPV 
types persist in the infected cell, cancer can arise [15]. Transformation is associated with the 
expression of the viral oncogenes E6 and E7 which are able to deregulate the host’s cell cycle 
and to interfere with senescence and apoptosis (further discussed below). Both the E6 and E7 
oncoproteins have shown transforming potential in various experimental systems [16, 17] and 
their continuous expression is necessary to sustain the malignant phenotype of HPV-positive 
cancer cells [18]. Typically, E6/E7 can give rise to precursor lesions named cervical 
intraepithelial neoplasias (CINs) [19], which are classified from CIN1 to CIN3 depending on 
an increasing grade of cellular dysplasia. In many cases, they can spontaneously regress, but a 
fraction of CIN3 lesions can progress to invasive cancer (Figure 1) [20].  
During progression from CIN1 to CIN3 and cervical cancer, E6 and E7 expression often 
increases [21]. HPV E6/E7 expression is usually repressed by the viral E2 protein [22]. 
Oncogenic HPVs can evade this repression through integration of the viral DNA in the host 
genome which typically results in the loss of the E2 open reading frame (ORF). As a 
consequence, the expression of E6/E7 increases. Most cervical cancers contain one or more 
copies of HPV integrated in the host genome. In HPV18-positive cervical cancers, HPV18 
DNA is almost always integrated. HPV16 integrates in 76% of HPV16-positive cervical 
cancer cases [23]. Interestingly, premalignant lesions usually contain episomal viral DNA, 
whereas in malignant tumours most often integrated HPV DNA is found [24, 25]. This 
suggests that viral integration occurs in cells that transit from non-malignant to malignant 
tumour cells. 
It should be noted, however, that the percentage of women infected with high-risk HPVs 
which eventually develop cancer is low [26]. Furthermore, the prevalence of infected women 
is greatest between the age of 25 and 35 years, whereas cervical cancer is more common in 
women older than 45 years, indicating that the progression from initial infection to cancer 
usually is a process over decades [27]. This suggests that there are additional events involved 
in carcinogenesis than HPV infection alone [28]. E6/E7 may support oncogenesis, for 
example by inducing genetic instability [29] and the accumulation of these genetic errors may 
then facilitate cancer progression.  
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Figure 1: HPV-induced carcinogenesis. Persistent infection with HPV can lead to the formation of 
premalignant precursor lesions. E6/E7 expression is increased during progression from CIN1 to 
invasive cancer. Malignant tumours often contain integrated HPV DNA. Image modified from [30]. 
 
1.3 HPV oncogenes E6 and E7 
The E6 and E7 oncoproteins are essential for HPV-linked oncogenesis and interfere with 
crucial cellular tumour suppressor pathways. Among other targets, E7 is able to bind to the 
retinoblastoma protein (pRb) and thereby deregulates the cell cycle [31]. pRb is a tumour 
suppressor involved in the negative regulation of cell cycle transition from G1 to S phase. It 
binds to the transcription factor E2F and thereby prevents the induction of E2F-stimulated 
genes which can promote cell cycle progression into S phase [32]. Usually, cells under an 
abnormal growth stimulus, as exerted by an oncogene, are predisposed to undergo apoptosis 
[33], which has also been observed in cells overexpressing E7 alone (Figure 2) [34]. 
However, apoptosis is blocked by E6 as it mediates the degradation of the pro-apoptotic p53 
protein [35, 36]. In specific, E6 forms a complex with the cellular ubiquitin ligase 
E6-associated protein (E6AP) and subsequently undergoes conformational changes rendering 
it competent to bind p53. The complex E6/E6AP then recruits p53 and induces its 
proteasomal degradation.  
These considerations indicate that the HPV E6 and E7 oncogenes can cooperate during 
carcinogenesis and, in line with this, it has been found that the transforming capacities of E6 
and E7 are enhanced when they are expressed together, compared to the expression of E6 or 
E7 alone [37, 38]. Moreover, silencing E6 and E7 rapidly induces senescence, an irreversible 
growth arrest, in HPV-positive cells [39]. This indicates that not only the transformation but 
also the maintenance of the malignant phenotype of HPV-positive cancer cells depends on 
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E6/E7 expression, i.e. the cells are “oncogene-addicted” [40]. Thus, E6 and E7 should be 
promising therapeutic targets for both immunotherapeutic approaches and for the generation 
of specific E6/E7 inhibitors.  
 
Figure 2: Cooperation of HPV E6 and E7 oncoproteins during oncogenesis. E7 deregulates the 
cell cycle through inhibition of pRb. Reactive apoptosis is prevented by E6, which forms a complex 
with E6AP and p53 and subsequently induces p53 degradation. Adapted from [40]. 
 
1.4 Therapy of HPV-positive cervical cancer 
Precancerous lesions and cervical cancers are usually removed surgically. In more advanced 
cancers the concomitant treatment with cisplatin-based chemoradiotherapy can be indicated 
[41]. However, given the role of E6/E7 in the transformation and growth, HPV-positive 
cancers could be particularly vulnerable to therapeutic strategies that target E6 and E7. These 
approaches should in principle be highly specific treatments, since the viral proteins are only 
expressed in HPV-positive preneoplastic and neoplastic lesions whereas uninfected, healthy 
tissue would not be affected. Immunotherapeutic approaches have been developed that deliver 
immunogenic epitopes of E6/E7 to the immune cells [42]. Such vaccines were promising in 
animal models and were also able to generate an HPV-specific cytotoxic T-cell response in 
some patients. However, the tumour regression is minimal and the clinical outcome does not 
correlate with T-cell response [43]. An explanation for the thus limited success of 
immunotherapy of HPV-positive cancers might be that oncogenic HPVs have developed 
sophisticated mechanisms to evade the immune system, such as generating an 
immunosuppressive environment [42] or interfering with the antigen-presenting machinery 
[44]. 
 7 
 
Introduction 
Several approaches are currently pursued which aim to inactivate E6/E7 expression or 
function, for example via siRNA [45] or molecules that impair the interaction of E6 with 
E6AP [46, 47]. Structural analyses of HPV16 E6 and the E6/E6AP/p53 complex revealed an 
E6AP binding pocket in the E6 protein [35]. Interestingly, this binding pocket can be targeted 
with molecules that inhibit the formation of the E6/E6AP/p53 complex and thus p53 is 
reconstituted [48]. p53 then initiates apoptosis.  
Collectively, these findings suggest that HPV E6 and E7 are promising targets for the 
treatment of HPV-positive cancer cells [40]. However, such therapies might be complicated 
by the fact, that many cervical cancers, similar to other tumours entities, contain hypoxic 
regions [49]. It is known that tumour hypoxia is correlated with higher resistance towards 
therapy [50]. 
1.5 Tumour hypoxia 
Hypoxia is characterised by a median oxygen concentration below 2% in comparison to 4-9% 
oxygen (“physoxia”) in most normal tissues [51]. Two major forms of hypoxia can be 
distinguished: chronic hypoxia due to diffusion limitations and cycling hypoxia due to 
perfusion limitations. Chronic hypoxia is caused by an enlarged distance of a cell from the 
blood vessel. Diffusion of oxygen in tissues can only reach as far as 100-200 µm [52], 
meaning that a tumour cell which is further than 200 µm away from a blood vessel is 
inadequately supplied with oxygen. Tumours that suffer from chronic hypoxia respond by 
enhancing the generation of new blood vessels (angiogenesis). However, in comparison to 
normal vasculature, the architecture of tumour blood vessels is both structurally and 
functionally abnormal [52]. This can lead to an inadequate perfusion of the microvessels (e.g. 
through temporary partial or total occlusions by blood cells) which exposes neighbouring 
tumour cells to repeated cycles of hypoxia and reoxygenation, called cycling hypoxia [53].  
Hypoxic tumours usually have a poor clinical prognosis which might be explained by 
processes that are altered under hypoxic conditions [53]: (1) increased genetic instability due 
to elevated reactive oxygen species (ROS) levels [54] and downregulated DNA repair 
mechanisms [55], (2) metabolic switch to increased glycolysis [56], (3) suppression of 
apoptosis [57] and senescence [58], (4) activation of autophagy [59], (5) induction of 
angiogenesis [60] and (6) the induction of invasion and migration [61]. These mechanisms 
can support the evolution of more aggressive and resistant tumour cells which constitutes a 
major obstacle for the treatment of hypoxic tumours [53]. 
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Furthermore, cells under hypoxic conditions are more resistant to radiotherapy (RT) and 
chemotherapy (CT) [50]. On the one hand resistance to RT can be caused by the lack of 
molecular oxygen which is needed to manifest the irradiation-induced DNA damage [62]. On 
the other hand resistance to CT can be related to the lack of blood vessels that are needed to 
transport chemotherapeutic drugs [63] or to the upregulation of drug efflux proteins in 
hypoxic cells [64]. Furthermore, chemotherapeutic drugs often act by targeting dividing cells 
but tumour cell proliferation can be inhibited under hypoxic conditions [64]. Therapeutic 
strategies have been developed in which radiotherapy is combined with inhalation of 
hyperoxic gas and the vasodilator nicotinamide in order to increase the oxygen availability in 
the tissue [65, 66]. However, although promising, these approaches have eventually been 
discontinued due to the complex technical requirements and poor patient compliance [67]. 
Thus, there is a great need for therapies that can target hypoxic tumour cells and cooperate 
with radio- and chemotherapy. 
1.6 Hypoxia in cervical cancer 
Cervical cancers typically show a heterogeneous distribution of better and less ventilated 
regions. More than 60% of the tumours contain hypoxic and/or anoxic (0% oxygen) regions. 
The median oxygen concentration in cervical cancer is around 1.2% in comparison to 5.6% in 
the normal cervix [68]. A major weakness of many functional studies on HPV-linked 
carcinogenesis is that they are conducted under standard cell culture conditions at 20% 
oxygen which does not reflect the conditions in a tumour.  
Previous work of our lab has shown that HPV-positive cancer cells strongly downregulate E6 
and E7 under hypoxic conditions [39]. Interestingly, other than under normoxia, repression of 
E6/E7 under hypoxic conditions does not result in senescence, but in a reversible state of 
dormancy and the cells resume proliferation upon reoxygenation. This could render therapy of 
hypoxic HPV-positive tumours even more difficult, since not only RT and CT are less 
efficient in hypoxic tumour regions, but also treatment with prospective E6/E7 inhibitors or 
E6/E7 targeting immunotherapeutics may fail, since the viral target proteins are no longer 
expressed in hypoxic tumour cells. Moreover, the hypoxia-induced dormancy of 
HPV-positive cancer cells is reversible, suggesting that upon reoxygenation (e.g. through 
neovascularisation or therapy-induced shrinkage of the tumour) these cells could serve as a 
reservoir for tumour recurrence.  
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1.7 Senescence 
The induction of senescence in tumour cells is considered to be a promising strategy for 
tumour therapy [69]. Cellular senescence can be categorised into replicative and premature 
senescence. Replicative senescence was first described by Hayflick and Moorhead in human 
fibroblasts [70]. They noticed an irreversible loss of the proliferative potential of cells after a 
certain number of cell doublings. Today it is known that replicative cellular senescence is 
caused by the shortening of telomeres which occurs during each cell cycle [71]. When 
telomeres reach a critical length (referred to as the Hayflick limit), cells undergo senescence. 
On the contrary, premature senescence happens without the loss of telomeres and can by 
induced by a plethora of intrinsic and extrinsic factors, including oxidative stress, DNA 
damage, mitochondrial dysfunction, oncogene activation, loss of tumour suppressors and also 
treatment with radio- and chemotherapy [72]. In general, senescence is characterised by a 
stable growth arrest accompanied by certain phenotypic alterations, such as 
senescence-associated ß-galactosidase (SA-ß-gal) activity, a large, flattened and sometimes 
multinucleated morphology of the cells, chromatin remodelling and a complex 
pro-inflammatory secretome [72]. 
Senescence can be induced and maintained by the p16/pRb and p53/p21 tumour suppressor 
pathways [73]. p53 is induced by telomeric attrition, oncogenic and oxidative stress. As a 
response to DNA damage a kinase cascade involving ATM, ATR, CHK1 and CHK2 is 
initiated which eventually activates p53. p53 subsequently induces the transcription of the 
cyclin-dependent kinase inhibitor p21 [74], which in turn blocks the cell cycle [75]. In 
comparison to a transient increase of p53 which results in a transient G1 arrest to allow DNA 
repair, senescence is characterised by sustained induction of p53 [76, 77]. Other proteins 
involved in senescence induction are encoded by the INK4/ARF locus. p16 (INK4a) and p15 
(INK4b) are cyclin-dependent kinase inhibitors similar to p21 [78]. ARF is able to sequester 
MDM2, a ubiquitin ligase involved in the degradation of p53 [79, 80]. Thus, ARF activation 
stabilises p53. In young, normal cells the INK4/ARF locus is not transcribed due to epigenetic 
silencing [81]. During senescence, the repressive mark is removed leading to the induction of 
INK4/ARF transcription [81]. p16 expression correlates with both aging and senescence and is 
therefore one of the most widely used senescence marker [82].  
Notably, in HPV-positive cancer cells, the MDM2-mediated degradation of p53 is not active 
and p53 is uniquely degraded via the E6/E6AP complex [83]. Moreover, p16 expression is 
upregulated in HPV-positive cancer cells, since E7 inhibits pRb which results in p16 
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overexpression [84]. Hence, upregulated p16 is actually used as a surrogate marker for the 
presence of HPV DNA [85] and cannot be employed as a senescence marker in HPV-positive 
cells. 
Blagosklonny et al. [86] proposed a model which explains senescence as a two-step process. 
First, cells reversibly arrest due to a proliferative halt in the presence of conflicting pro-and 
anti-proliferative signals. Second, the cells undergo “geroconversion” into an irreversible 
growth arrest (senescence). This latter step is dependent on mTOR (mechanistic target of 
rapamycin) signalling. This scenario is mirrored in HPV-positive cancer cells [40]. E6 and E7 
repression leads to a proliferative halt due to the reconstitution of p53 (leading to p21 
activation) and pRb. However, in these cells mTOR signalling is maintained which represents 
a conflicting pro-proliferative stimulus (first step) and also allows geroconversion of the cells 
(second step). Importantly, mTOR signalling is impaired under hypoxia which allows hypoxic 
HPV-positive cells to evade senescence and to induce a reversible state of dormancy [39, 40]. 
These results also suggest that by circumventing the mTOR-dependency of senescence, 
hypoxic tumour cells could be sensitised to senescence-inducing therapies. This could be 
achieved by identifying agents that restore mTOR signalling under hypoxia, or agents that can 
induce senescence in an mTOR-independent manner (Figure 3). 
Figure 3: Possible strategies to target 
normoxic and hypoxic HPV-positive 
cancer cells. HPV-positive cancer cells 
could be targeted with prospective E6/E7 
inhibitors which results in senescence 
induction in oxygenised cells. Under 
hypoxic conditions, where mTOR 
signalling is impaired, therapeutic 
approaches to induce senescence would 
need to restore mTOR signalling or induce 
senescence independent of mTOR. Image 
modified from [40]. 
 
 
mTOR-independent induction of senescence could have an additional benefit. Senescent cells 
secrete a plethora of pro-inflammatory factors that together account for the 
senescence-associated secretory phenotype (SASP) [87]. The composition of the SASP 
strongly depends on the cellular background of the senescent cell and the senescence-inducing 
stimulus. The function of the SASP is double-edged. Senescent cells secrete factors that 
reinforce senescence by an autocrine positive-feedback loop. Interestingly, also surrounding 
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cells then could undergo senescence as a response to the SASP [88]. Both would support the 
anti-tumourigenic effect of senescence-inducing therapies. Furthermore, the SASP has a 
pro-inflammatory nature. On the one hand this can be anti-tumourigenic due the recruitment 
of cells that remove the senescent cell. On the other hand sustained inflammation can be 
pro-tumourigenic. Further studies have also shown that senescent fibroblasts can promote the 
proliferation of tumour cells [89]. Interestingly, the mTOR pathway, more specific the mTOR 
complex 1 (mTORC1), is responsible for the induction of this pro-tumourigenic SASP [90]. 
Thus, agents that are able to induce mTOR-independent senescence could be particularly 
attractive for anti-cancer therapy, since they may not only target hypoxic tumour cells, but 
also prevent secretion of a pro-tumourigenic SASP by stromal fibroblasts. 
1.8 Iron metabolism 
Iron is an essential element needed for multiple processes in the cell. It is used as a co-factor 
in proteins that are responsible for oxidative phosphorylation (iron-sulphur clusters), DNA 
synthesis (ribonucleotide reductase) and oxygen binding and transport (haemoglobin) to name 
a few. Its biological significance mainly relies on the fact that iron is a transition metal which 
fluctuates between two oxidation states: ferrous iron (Fe
2+
) and ferric iron (Fe
3+
). However, 
this characteristic can also be toxic to the body since the oxidation-reduction processes 
generate ROS through the Fenton reaction [91]: 
 Fe
2+
 + H2O2  Fe
3+
 + OH
-
 + HO
•  (1) 
 Fe3+ + H2O2  Fe
2+
 + H
+
 + HOO
••   (2) 
In the presence of hydrogen peroxide, ferrous iron can be oxidised to ferric iron which results 
in the generation of a hydroxide ion and a hydroxyl radical (1). In the next step (2) ferric iron 
is reduced back to ferrous iron and generates a proton and a hydroperoxyl radical. The net 
effect is the generation of water (OH
-
 + H
+
) and two different oxygen radicals. These free 
radicals can cause damage to lipid membranes, proteins and nucleic acids of a cell. Since iron 
can be both beneficial and detrimental its levels need to be tightly regulated. 
Each day, 25 mg of iron are needed for erythropoiesis, but only 1-2 mg are absorbed through 
the intestine [92]. The remaining iron is recycled from cells through macrophages and 
released from iron storage tissues such as the liver. In enterocytes dietary iron is absorbed via 
divalent metal transporter 1 (DMT1) and transported to the blood by ferroportin 1 (FPN1), a 
transmembrane protein that is the only known iron exporter to date [93]. Iron efflux from cells 
is tightly regulated by hepcidin, which is synthesised in the liver and promotes the 
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internalisation and degradation of ferroportin [93]. Ferroportin is coupled to ferroxidases 
which oxidise Fe
2+
 to Fe
3+
. This oxidation step is necessary since the iron carrier transferrin 
(TF) in the plasma can only bind ferric iron (Fe
3+
) [94].  
Two ions of ferric iron bind to apo-transferrin to generate holo-transferrin (Figure 4). Iron 
uptake then occurs via receptor-mediated endocytosis in which two holo-transferrins bind to 
the homodimeric transferrin receptor (TFR, also known as TFRC or CD71) [95]. Two types 
of TFRs are known: TFR1 and TFR2. The expression of TFR2 is mainly limited to 
hepatocytes and iron-absorbing cells of the duodenum. After endocytosis and acidification of 
the endosome iron is released from transferrin due the pH-dependent binding capacity of 
transferrin [96]. Ferric iron is subsequently reduced to Fe
2+
 by the metalloreductase STEAP3 
(six-transmembrane epithelial antigen of prostate 3) [97] and transported into the cytosol via 
DMT1 where it can reach different destinations (see 1.9). The iron-free TF remains bound to 
TFR in the endosome and is recycled back to the cell membrane. There it is released from 
TFR and can sequester more iron [95, 98]. 
 
Figure 4: Cellular iron metabolism. Non-transferrin bound iron generates cytotoxic ROS and thus 
needs to be bound by transferrin. After receptor-mediated endocytosis, release and reduction of ferric 
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iron, iron is transported as ferrous into the cytoplasm where it feeds into the labile iron pool. From 
there it can be used in diverse biological processes, stored in ferritin or exported via ferroportin. Iron 
efflux is regulated by hepcidin which regulates the degradation of ferroportin. (Abbreviations: NTBI, 
non-transferrin bound iron; ROS, reactive oxygen species; TF, transferrin; TFR, transferrin receptor; 
DMT1, divalent metal transporter 1; LIP, labile iron pool; IRP, iron regulatory protein; IRE, iron 
responsive element). Image modified from [99]. 
 
1.9 Intracellular iron 
The absorbed iron feeds into the so called “labile iron pool” (LIP). It consists of Fe2+ which 
can be directly incorporated into iron-dependent enzymes or used to control transcription of 
iron-regulated genes. Many attempts have been made to characterise the labile iron pool, but 
this has proven difficult due to its nature of being an intermediate or transitory pool between 
extracellular iron and iron that is associated with intracellular proteins [100]. In the broadest 
definition the labile iron pool comprises iron that can potentially participate in redox-reactions 
and can be scavenged by iron chelators. This portion is only 5% of a cell’s total iron content, 
which is between 50 µM and 100 µM [100].  
In order to keep the labile iron pool relatively low, iron can either be exported via ferroportin 
or stored in ferritin which is the key player to detoxify excess intracellular iron and is 
therefore expressed in almost all tissues [92]. It consists of tissue-dependent ratios of 24 
heavy (H) and light (L) ferritin subunits encoded by FTH and FTL, respectively. Ferritin can 
sequester up to 4500 atoms of ferric iron [101, 102]. The H subunit oxidises Fe
2+
 from the 
labile iron pool to Fe
3+
 [103] and the L subunit is responsible for the stabilisation of the 
ferritin complex and it facilitates the uptake of iron into the ferritin protein [104, 105].  
The levels of iron in the labile iron pool are tightly regulated by the IRE/IRP (iron responsive 
element / iron regulatory protein) system (reviewed in [106-108]). IREs are highly conserved 
sequences (25-30 nucleotides) in the untranslated regions (UTRs) of mRNAs that encode for 
iron-dependent proteins such as ferritin and transferrin receptor 1. They represent binding 
sites for the two iron regulatory proteins: IRP1 and IRP2, encoded by ACO1 and IREB2, 
respectively. When iron is decreased, IRP1 and IRP2 bind to IREs with high affinity. 
Depending on the location of IREs at the mRNAs, IRP binding inhibits translation or 
degradation of the mRNAs (Figure 5). In the case of ferritin (encoded by FTH and FTL) the 
IRE is located at the 5’ UTR [109]. In the absence of iron, IRP binds to the IRE and impedes 
translation initiation, resulting in reduced expression of the iron storage protein. In the mRNA 
of TFR1 multiple IREs are located at the 3’ UTR of the mRNA [110] close to a recognition 
site for endonucleases [111]. Bound IRPs at the IREs of TFR1 prevent endonucleolytic 
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cleavage of the mRNA and thus stabilise the mRNA and elevate expression of TFR1 in order 
to increase iron uptake. Vice versa, in iron-replete conditions, iron binds to IRPs and prevents 
IRE binding. Thus, translation of ferritin is initiated whereas TFR1 mRNA is degraded.  
 
Figure 5: The IRE/IRP system. In iron-deficient cells, IRPs bind IREs. While binding of IREs at the 
5’ UTR inhibits translation, binding of IREs at the 3’ UTR stabilises the target mRNA. In the presence 
of iron IRPs dissociate from IREs. (Abbreviations: IRP, iron regulatory protein; IRE, iron responsive 
element; FPN1, ferroportin-1; FTH1, ferritin, heavy polypeptide 1; FTL, ferritin light polypeptide; 
HIF2A, hypoxia-inducible factor 2α; TFRC, transferrin receptor). Image from [112]. 
 
Interestingly, the assembly of IRP1 with an iron-sulphur cluster converts IRP1 into an isoform 
of the cytosolic aconitase which is responsible for the isomerisation of citrate to isocitrate in 
the citric acid cycle [113]. These two functions of IRP1 are mutually exclusive and depend on 
the iron status of the cell. Both IRP1 and IRP2 RNA-binding capacities are regulated by iron. 
For IRP1, iron dictates the change in its function from binding IRE to aconitase without 
changing the expression of IRP1 protein, whereas IRP2 RNA-binding decreases in 
iron-replete cells due to iron-dependent proteasomal degradation of IRP2 [114]. Other 
IRE/IRP regulated mRNAs are among others ferroportin-1 (FPN1) and hypoxia-inducible 
factor-2α (HIF-2α) with a single IRE in the 5’ UTR (analogous to ferritin) and DMT1 with an 
IRE in the 3’ UTR (analogous to TFR1) [108]. Thus, upon iron deprivation FPN1 and HIF-2α 
are downregulated, whereas DMT1 expression is increased.  
In summary, to maintain the iron homoeostasis, the cell has developed a sophisticated system 
of iron-dependent enzymes that regulate the appropriate expression of proteins necessary for 
iron import, export and storage.  
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1.10 Iron and oxygen homoeostasis 
An important role of iron is the binding and transportation of oxygen in haemoglobin. Thus, it 
is not surprising that both iron and oxygen metabolism are coordinated. Hypoxia-inducible 
factors (HIFs) are the key mediators in these processes since they are regulated by both iron 
and oxygen levels [115]. HIF consists of two subunits, HIF-α and HIF-ß (also known as 
aryl-hydrocarbon-nuclear transporter, ARNT). Whereas HIF-ß is constitutively expressed, 
HIF-α expression is altered in response to changes in oxygen tension [116]. When oxygen is 
available, prolyl hydroxylases (PHDs) hydroxylate proline residues of HIF-α. which recruits 
the von Hippel-Lindau factor (VHL) leading to ubiquitination and proteasomal degradation of 
HIF-α [117]. Since hydroxylation is impaired under hypoxic conditions, HIF-α accumulates 
and initiates the transcription of target genes in order to adapt to hypoxia. PHDs are not only 
oxygen, but also iron-dependent. Thus, upon iron deprivation HIF-α is also stabilised.  
HIF-2α plays an important role in the crosstalk between iron metabolism and hypoxia. Upon 
hypoxia HIF-2α expression is increased due to stabilisation of the protein. However, in the 
absence of iron HIF-2α mRNA is not translated due to an IRE in its 5’ UTR [118]. Since 
HIF-2α is involved in the stimulation of erythropoietin synthesis for erythropoiesis this could 
be a mechanism to avoid erythrocyte production when iron is not available. Thus, on the one 
hand, iron levels are crucial for the cell’s response towards hypoxia. 
On the other hand, hypoxia can also alter the cell’s iron metabolism. Upon hypoxia the body 
induces erythropoiesis. To satisfy the demand of iron for this process, hepcidin expression is 
suppressed upon hypoxia and anaemia [119, 120]. The decrease of hepcidin stabilises 
ferroportin to elevate the efflux of iron from cells into the blood stream; for instance from 
duodenal enterocytes which absorb dietary iron and from macrophages which recycle and 
store iron from phagocytosed erythrocytes. Furthermore, HIF upregulates the expression of 
iron regulated genes such as TFR1 and DMT1 [121]. All together the plasma levels of iron 
increase, which then can be utilised by erythroid precursor cells during erythropoiesis. 
1.11 Iron and cancer 
As discussed above, iron generates reactive oxygen species that are able to cause DNA 
mutations. Furthermore, iron is required by ribonucleotide reductase (see 1.14), an essential 
enzyme in DNA synthesis and cell proliferation. Consequently, iron can not only accelerate 
tumour initiation but it is also needed to support tumour growth. Various studies have linked 
increased iron levels to greater susceptibility to develop tumours (reviewed by Torti and Torti 
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[122]). Given the role of iron in proliferation it is not surprising that tumour cells have 
developed mechanisms to increase their iron uptake. TFR1 expression is upregulated in many 
cancers including lymphomas [123], gliomas [124], lung cancer [125], breast cancer [126] 
and others. DMT1 is upregulated to increase iron influx and HAMP (encoding hepcidin) 
expression is increased to decrease iron efflux through repression of ferroportin [127, 128]. 
Additionally, the expression of ferroportin is downregulated [128]. Furthermore, IRP1 and 
IRP2 overexpression not only enhances tumour growth in xenograft models [129, 130], but 
has also been observed in breast cancer [131]. IRP overexpression elevates TFR1 expression 
but also decreases ferritin expression. The coordinated increase of iron influx together with 
the reduction of the iron storage protein has been suggested to increase the availability of 
intracellular iron for metabolic processes in cancer cells [132]. Taken together cancer cells 
have altered the iron metabolism to increase their labile iron pool in order to satisfy their 
demand for iron. Given the cancer cells’ avidity for iron the question arises whether iron 
chelators could serve as anti-tumour agents.  
1.12 Iron chelators 
Iron chelators are small molecules which bind iron with high affinity. Iron ions have six 
coordination sites that can be bound by iron chelators. An iron chelator that occupies all six 
coordination sites is called a hexadentate iron chelator (ratio chelator:iron = 1:1, Figure 6). A 
tridentate chelator occupies three coordination sites (ratio = 2:1) and a bidentate chelator 
occupies two coordination sites which results in a ratio of 3:1.  
 
Figure 6: Complexes of iron chelators and iron ions. Depending on the number of occupied 
coordination sites at the iron ion, iron chelators (red) can be classified as bidentate, tridentate or 
hexadentate iron chelators.  
 
Iron chelators are used in the clinic to treat iron overload diseases such as hereditary 
haemochromatosis and beta-thalassemia, or iron intoxication due to abuse consumption of 
iron. Currently three iron chelators are used in the clinic for iron chelation therapy: 
deferoxamine (DFO), deferiprone and deferasirox. DFO is a hexadentate Fe
3+
 chelator [133], 
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approved by the FDA for long-term iron chelation therapy. Since it is a hydrophilic molecule 
it cannot penetrate the cell membrane and depends on endocytosis [134, 135]. Unfortunately it 
has a short plasma half-life and needs to be administered by frequent and lengthy injections 
which leads to suboptimal patient compliance [136]. Deferiprone and deferasirox are both 
orally available. Despite the improved acceptance from patients, deferiprone is not used as 
standard therapy for ß-thalassemia, since its efficiency is lower than DFO [137]. Deferasirox, 
however, seems to have similar efficacies in comparison to DFO and due to the oral 
application it could become a preferable choice for iron chelation therapy [138]. Systemic or 
oral gavage of iron chelators leads to the reduction of serum iron levels which causes side 
effects like gastrointestinal toxicities, kidney and liver damage [139]. Thus, to treat diseases 
of the skin and mucosa, the use of topical iron chelators could allow the application of high 
doses without side effects at the systemic level as observed after systemic or oral application. 
Notably, a topically applicable antimycotic drug, called ciclopirox, has recently been 
identified as an iron chelator [140]. 
1.13 Ciclopirox (CPX) 
Ciclopirox (6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone) is an antifungal agent to treat 
mycoses of the skin, nails and also mucosa. It has been used in the clinic for decades and 
shows a very good safety profile [141]. The antimycotic activity of CPX differs from other 
fungicides which primarily target the cell membrane by binding to the membrane component 
ergosterol or by interfering with its biosynthesis [142]. CPX has been shown to not only 
disrupt the cell membrane [143], but also to target different metabolic processes (e.g. 
respiration) [144] and intracellular pathways regulating DNA repair and cell division in yeast 
[145]. These activities are presumably attributed to the ability of CPX to chelate intracellular 
iron. However, the exact mechanism of action still remains to be elucidated.  
CPX is a bidentate, lipophilic iron chelator [146]. It preferentially complexes ferric iron (Fe
3+
) 
[144] and semiquantitative analyses show that CPX has an even higher binding capacity of 
ferric iron than DFO [146]. CPX is often used in the form of its olamine salt. The olamine 
entity improves the solubility in water but does not modify the pharmacological properties of 
CPX in any respect [141]. Thus, the term CPX will be used for both forms in the following. 
CPX can be applied as lacquer, shampoo, gel and vaginal suppository [141].  
Notably, CPX has recently gained considerable interest in cancer research since it may also 
possess anti-tumourigenic potential. In multiple cell lines, CPX can induce cell cycle arrest in 
G0/G1 phase and apoptosis. Although the underlying mechanisms are not well understood, 
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some candidate molecular targets that may mediate these effects have been identified. For 
instance, CPX has been described to inhibit ribonucleotide reductase (RR), which catalyses 
the rate-limiting step in DNA synthesis and depends on iron (further discussed in 1.14) [147]. 
Another target is the deoxyhypusine hydroxylase (DOHH) [148]. Similar to RR, DOOH is 
also iron-dependent. DOHH is essential for the maturation of the eukaryotic translation 
initiation factor 5A (eIF5A). CPX blocks DOHH and thereby induces cell cycle arrest [148]. 
Furthermore, CPX downregulates a plethora of cyclins and cyclin-dependent kinases and 
induces p21 expression which results in a cell cycle arrest [149]. In addition, 
apoptosis-inducing properties of CPX have been reported which are associated to the 
downregulation of the anti-apoptotic proteins survivin and BCL-XL and enhanced cleavage of 
BCL-2 [149]. Other pathways described to be suppressed by CPX are Wnt/ß-catenin [150, 
151], VEGF [152], mTOR [153] and myc [154].  
Taken together CPX appear to have a broad spectrum of potential targets that are involved in 
carcinogenesis. Since CPX may have anti-tumourigenic potential it has been subjected to in 
vivo studies. It was revealed that CPX is competent to inhibit tumour growth in various 
xenograft models [149, 151, 155, 156]. After these promising studies, CPX has further been 
promoted to clinical phase I studies. The very first phase I study was conducted in patients 
with relapsed or refractory haematologic malignancies [157]. CPX was given orally and two 
out of 24 patients showed haematological improvements, although neither complete nor 
partial remission could be achieved. Serum concentrations of CPX could not be further 
elevated due to gastrointestinal toxicities which could explain the limited clinical benefit. In 
January 2018, a second clinical trial started in order to evaluate the safety and efficacy of a 
ciclopirox prodrug given intravenously to patients with solid tumours (ClinicalTrials.gov 
identifier: NCT003348514).  
Upon topical application, about 7% of the applied dose can be detected in the skin of rats 
during an 8 h exposure of CPX with the maximum concentration after 2 h. Notably, only 
0.15% of the applied dose actually reaches the systemic circulation with highest 
concentrations 3 h after application [158]. Thus, it is very unlikely to reach high systemic 
concentrations of CPX upon topical application. Although the absorption in the mucosa of the 
vagina of female patients is higher with up to 9% [141], the absorption rate is in general 
relatively low. Nonetheless, CPX has a high penetration capacity [159], since it can reach 
deep layers of the skin where it still has concentrations that are high enough to efficiently kill 
fungi. Thus, if CPX also exerts anti-tumourigenic effects on HPV-transformed cells, it might 
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serve as a promising new drug for the topical treatment of HPV-positive (pre)neoplastic 
lesions of the cervix.  
1.14 Ribonucleotide reductase (RR) 
Particularly interesting are reports suggesting that CPX can block the enzyme ribonucleotide 
reductase (RR), more specifically its iron-containing subunit M2 [147, 160]. RR has been 
suggested to be a promising target for anti-cancer therapy, since RR inhibitors possess 
anti-tumour activities both in vitro and in vivo [161] by inducing therapeutically desired 
phenotypes, including cell cycle arrest [162], senescence [163, 164] and apoptosis [165]. 
Notably, inhibition of RRM2 induces a DNA damage response [163] and interferes with DNA 
repair [166]. Interestingly, RR inhibition has also been investigated in cervical cancer cell 
lines and animal models [167] resulting in G1 cell cycle arrest and apoptosis in vitro and 
inhibition of tumour formation in xenograft models [167]. 
At the biochemical level, RR is responsible for the conversion of ribonucleoside di- or 
triphosphates (rNDPs/rNTPs) into deoxyribonucleoside di- or triphosphates (dNDPs/dNTPs) 
that are needed for DNA synthesis [168, 169]. It consists of two subunits RRM1 (also known 
as R1 or M1) and two M2 subunits (also known as R2), forming a heterotetramer (Figure 7). 
RRM1 contains the substrate binding site for rNDPs/rNTPs. Furthermore, it contains two 
allosteric sites - one regulates the specificity towards any of the four possible nucleosides, the 
other regulates the overall activity of RRM1 [170, 171]. The conversion of nucleoside to 
deoxynucleoside occurs via a free radical reaction for which a tyrosyl radical at M2 is 
essential. A diferric iron centre stabilises the tyrosyl radical [172]. 
 
Figure 7: Ribonucleotide reductase. 
Ribonucleotide reductase (RR) consists of two 
RRM1 and two M2 subunits. M2 contains a 
tyrosyl radical which is essential for its catalytic 
activity and which is stabilised by a diferric centre. 
Two isoforms of M2 exist: RRM2 and p53R2. 
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Interestingly, M2 exists in two forms: RRM2 and p53R2 (also known as RRM2B) [173]. Both 
possess the diferric iron and tyrosyl radical centre and substitute for each other during 
dNDP/dNTP synthesis [174]. However, while RRM2 is cell cycle-dependent and maximally 
expressed during S phase, p53R2 expression can be induced by p53. RRM2 is thus needed for 
DNA synthesis during cell cycle progression and p53R2 provides dNDPs/dNTPs for normal 
DNA repair [175, 176] and mitochondrial DNA synthesis [177] in non-proliferating cells.  
Given their role in cell proliferation it is not surprising that RRM1, RRM2 and p53R2 
overexpression is observed in various cancers and that expression correlates with tumour 
grade [178]. Several inhibitors of RR have therefore been developed into anti-cancer drugs 
(reviewed in [179]). They can be classified in two groups: RRM1 inhibitors and 
RRM2/p53R2 inhibitors [179]. RRM1 inhibitors are often nucleoside analogues (e.g. 
gemcitabine) and thereby allosterically inhibit RR activity. RRM2/p53R2 can be targeted with 
iron chelators since the iron centre is essential for the enzymatic activity. Another approach is 
to scavenge the tyrosyl radical, for example by hydroxyurea (HU) [180]. HU was one of the 
first agents to treat cancer and has therefore been evaluated in many clinical studies (reviewed 
in [179]). Interestingly, the majority of these studies were performed in cervical cancer, 
especially in combinatorial treatments with radiotherapy. HU was able to sensitise cancers to 
RT and for some time it was used as standard of care to treat locally advanced cervical cancer. 
However, HU was replaced by cisplatin due to increased clinical benefit and less toxicities 
[181].  
These considerations suggest that CPX, as an iron chelator, could exert anti-tumourigenic 
activities by means of RRM2/p53R2 inhibition. Furthermore, it might be possible that CPX 
could serve as a radiotherapy sensitiser, similar to HU.  
1.15 Research objectives 
Iron is essential for the proliferation of cells. Consequently, in order to facilitate tumour 
growth, cancer cells alter their iron metabolism to elevate intracellular iron levels. To date, it 
is not known whether the availability of iron affects cervical cancer, in specific the crosstalk 
between cellular iron metabolism and oncogenic HPVs is unknown. Hence, this work will 
examine the phenotypic consequences of iron chelators on HPV-positive cervical cancer cells. 
A focus will be put on the antimycotic drug ciclopirox which is a topically applicable iron 
chelator and may therefore be particularly suitable for the treatment of cervical 
(pre)neoplasias of the mucosa.  
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The following questions will be addressed in this dissertation: 
 What are the effects of iron chelators on the expression of the viral oncogenes E6 and 
E7?  
Time and dose kinetics of different iron chelators will be performed and expression of 
E6 and E7 will be analysed on protein and mRNA level. 
 What are the phenotypic consequences of iron deprivation?  
Proliferation assays, cell cycle analyses, senescence and apoptosis assays will be 
performed to examine the cellular response to CPX treatment. The dependence of the 
observed effects on iron deprivation will be tested. Since standard 2D cell culture 
does not reflect the heterogeneity of a tumour, also 3D cell spheroids will be 
established and analysed.  
 Do hypoxic cervical cancer cells respond to CPX?  
Many cervical cancers are known to harbour hypoxic regions which can lead to 
increased resistance towards anti-tumour therapy. Hence, an emphasis will be placed 
on comparative analyses of CPX treatment under normoxic or hypoxic conditions. 
Furthermore, it will be investigated whether CPX can cooperate with radio- and 
chemotherapy. 
 What are the cellular mechanisms that mediate the anti-tumourigenic effects of CPX? 
 Proteome analyses will be performed in order to identify signalling pathways that are 
affected by CPX treatment. 
The overall aims of this work are to gain new insights into virus/host cell crosstalk during 
HPV-linked carcinogenesis and to investigate whether iron chelators, most notably CPX, 
could serve as prospective therapeutic agents against HPV-positive cervical cancers.  
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2. Results 
2.1 Iron chelators repress E6 and E7 
To analyse the effect of iron chelators on HPV-positive cells, the expression of the viral 
oncogenes E6 and E7 was determined on mRNA and protein level upon treatment with the 
iron chelator deferoxamine (DFO). Furthermore, protein levels of the iron storage protein 
ferritin (more specific its heavy subunit) and TFR1 mRNA levels were assessed as indirect 
measurements of intracellular iron levels. Upon iron depletion it is expected that ferritin 
protein levels decrease and TFR1 mRNA amounts increase through the regulation by the 
IRE/IRP system (see Figure 5).  
HPV18-positive HeLa and HPV16-positive SiHa cells were treated with 100 µM DFO for 
24-72 h (Figure 8A, B). Interestingly, DFO strongly decreases viral oncoprotein expression in 
a time-dependent manner. Ferritin protein levels are reduced after DFO treatment, indicating 
that DFO depletes intracellular iron levels under treatment conditions. E6/E7 repression by 
DFO is independent of the HPV type, since it can be observed in both HeLa and SiHa cells.  
Furthermore, E6/E7 repression by DFO is also detectable on mRNA level as demonstrated by 
qRT-PCR analyses (Figure 8C, D). Relative E6/E7 mRNA levels were assessed with primers 
that recognise all three transcripts classes coding for HPV E6/E7 in HeLa and SiHa cells (see 
4.5.2) and the untreated control was set to 1.0 for each point of time. After 24 h HPV E6/E7 
mRNA levels moderately increase upon DFO treatment, although this is not reflected on 
protein level (Figure 8A, B). However, after 48 h treatment, a strong repression of E6/E7 
mRNA expression is detectable in both HeLa and SiHa cells, concomitantly with the strong 
downregulation of E6/E7 protein levels. TFR1 mRNA levels increase during the first 24 h. In 
line with the reduction of ferritin protein levels after 24 h, this indicates that iron chelation by 
DFO precedes E6/E7 repression. 
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Figure 8: Iron chelators repress HPV16 and HPV18 E6 and E7 expression. (A), (B) HeLa (A) and 
SiHa (B) cells were treated with 100 µM DFO for the indicated time periods. ß-actin served as loading 
control. (C), (D) Relative mRNA expression of HPV18 E6/E7 and TFR1 in HeLa (C) and HPV16 
E6/E7 and TFR1 in SiHa (D) cells upon 100 µM DFO treatment. Controls of the respective points of 
time were set to 1.0. One exemplary experiment is depicted. 
 
The results reveal that iron chelators possess the potential to strongly block HPV oncogene 
expression. To further corroborate this notion we analysed CPX, which - in contrast to DFO - 
can be applied topically and thus may be suitable for the treatment of HPV-induced 
(pre)neoplasias of the mucosa. 
HeLa and SiHa cells were treated with different concentrations of CPX for up to 48 h. 
Figure 9A and B show that, alike DFO, CPX strongly represses HPV16 and HPV18 E6 and 
E7 proteins in a dose- and time-dependent manner. In HeLa cells, a strong repression of E6 
and E7 occurs after 48 h with all tested concentrations and in SiHa cells, E6/E7 protein levels 
are strongly decreased after 24 h and 48 h exposure with CPX concentrations above 10 µM. 
E6 repression appears to precede E7 repression in HeLa cells since a slight downregulation of 
E6 can already be seen after 12 h and 24 h with 10 µM and 20 µM CPX whereas E7 protein 
levels are not affected at these points of time. Ferritin is downregulated by CPX in both cell 
lines, indicating that CPX indeed decreases intracellular iron levels under treatment 
conditions.  
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Relative E6/E7 mRNA levels were assessed in HeLa and SiHa cells and one representative 
experiment is shown for each cell line (Figure 9C and D, respectively) to depict the 
time-dependent regulation of E6/E7 and TFR1 transcription upon 10 µM CPX treatment. 
Similar as observed for DFO, E6/E7 mRNA levels increase after 24 h in HeLa and SiHa cells 
upon CPX treatment which, however, is not reflected on protein level (Figure 9A, B). After 
48 h and 72 h, the E6/E7 mRNA levels are strongly repressed in both cell lines. As expected, 
TFR1 mRNA levels increase with CPX treatment, except in SiHa cells after 72 h CPX 
treatment which might be related to the observation that cells undergo apoptosis at this point 
of time. Alike DFO treatment, iron deprivation by CPX precedes E6/E7 repression.  
For statistical analyses of the extent of E6/E7 mRNA repression, HeLa and SiHa cells were 
treated for 48 h with 10 µM CPX. Figure 9E illustrates the log2 fold change of HPV18 E6/E7 
and TFR1 expression of HeLa cells relative to solvent (EtOH)-treated cells. The mRNA levels 
of the solvent control were set to 1.0 (resulting in a log2 of 0). In HeLa E6/E7 mRNA is 
significantly repressed to a log2 of -2.9 with p<0.001; showing that CPX induces an almost 
90% reduction of HPV18 E6/E7 levels. A similar repression is induced by CPX in SiHa cells 
(Figure 9F) with a log2 fold change of -2.8 (p=0.003). TFR1 mRNA is significantly 
upregulated upon CPX treatment in both cell lines. 
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Figure 9: CPX represses HPV oncogene expression. (A), (B) Western blot analyses of HeLa (A) 
and SiHa (B) cells after CPX treatment. Cells were treated with 1-20 µM CPX for 12 h, 24 h or 48 h. 
Vinculin was used as loading control. (C), (D) Relative mRNA expression of TFR1 and HPV18 E6/E7 
(HeLa, C) or HPV16 E6/E7 (SiHa, D) after treatment with 10 µM CPX for the indicated time periods. 
One representative experiment is shown. (E), (F) For the point of time at 48 h the log2 fold change was 
calculated from 3-5 independent experiments treating HeLa (E) or SiHa (F) cells with 10 µM CPX. 
E6/E7 and TFR1 mRNA levels relative to the EtOH control (set to 1.0) are depicted after logarithmic 
transformation. Standard deviations are indicated, ***=p<0.001, **=p<0.01. 
 
To further corroborate that CPX-induced E6/E7 repression is caused by deprivation of iron, 
E7 protein expression was measured after treatment with CPX which has previously been 
complexed with iron or zinc (Figure 10A). Notably, when CPX was saturated with excess of 
two different iron donors - FeSO4 as a ferrous iron (Fe
2+
) donor or FAC as a ferric iron (Fe
3+
) 
donor - E7 repression is abrogated in HeLa cells. On the contrary, zinc is not able to impede 
the E7 repression. The treatment of cells with iron (as either Fe
2+
 or Fe
3+
) per se does not alter 
the expression of E7 (Figure 10B). Concomitant results were obtained in SiHa cells. 
Collectively, these observations support the notion that E6/E7 is repressed by iron deprivation 
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and the inhibition of viral oncogene expression through CPX is caused by its ability to chelate 
intracellular iron. 
 
Figure 10: Excess iron prevents CPX-induced E7 repression. (A) Western blot analyses of HPV18 
E7 and ferritin after 48 h treatment with 10 µM CPX in HeLa cells. Before treatment, CPX was 
complexed with 6.67 µM iron (FeSO4, FAC) or zinc (ZnSO4, ZnCl2). CPX binds iron at a ratio of 3:1 
[146]. 6.67 µM iron or zinc is equivalent to a twofold excess. (B) HeLa cells were treated with 
increasing concentrations of iron (FeSO4 and FAC) for 24 h and analysed for the E7 and ferritin 
expression. Vinculin was used as loading control. 
 
2.2 CPX inhibits cell proliferation 
Next, the phenotypic consequences of CPX treatment were investigated. Since E6 and E7 are 
essential for the growth of HPV-positive cancer cells [182], the effect of CPX treatment on 
the proliferation of HeLa and SiHa cells was investigated. Cell proliferation in 2D cell culture 
was assessed by determining the increase of cell nuclei count with the IncuCyte® system, 
using cells that express the fusion protein mCherry H2B. In comparison to untreated or EtOH 
(solvent control)-treated cells, CPX causes a dose-dependent inhibition of cell growth in both 
HeLa and SiHa cells (Figure 11A and B, respectively). Importantly, CPX not only inhibited 
cell growth in 2D cell culture, but also in 3D cell culture. For the generation of spheroids a 
protocol was established which includes seeding cells in an ultra-low attachment microplate 
and supplementing the medium with methylcellulose. The size of spheroids upon treatment 
with different concentrations of CPX was measured with the IncuCyte® system using the 
acquisition and analysis tool for spheroids. Figure 11C and D depict the increase of spheroid 
size upon CPX treatment. Representative brightfield images of HeLa and SiHa spheroids that 
were treated with 10 µM CPX are shown in Figure 11E and F. It can be observed that the 
spheroids not only do not increase in size but especially in SiHa spheroids a decrease is 
visible, suggesting that besides inhibition of proliferation there might also be a component of 
cell death. After 3 d of CPX treatment, spheroids were sectioned and stained for the 
proliferation marker Ki-67 (Figure 11G) which indicates that CPX strongly inhibits 
proliferation. Furthermore, ferritin was analysed and at least in the outer cell layers of the 
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spheroid there is a strong reduction of expression, indicating that CPX depletes these cells of 
iron. Corresponding results were obtained with SiHa spheroids.  
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Figure 11: CPX inhibits proliferation. (A), (B) Cell proliferation of HeLa mCherry H2B (A) and 
SiHa mCherry H2B (B) cells under 2D cell culture conditions upon treatment with 1-10 µM CPX. One 
representative experiment is shown. (C), (D) Size of HeLa (C) and SiHa (D) spheroids as assessed 
with the IncuCyte® system upon treatment with 2-10 µM CPX. On representative experiment is 
depicted. (E), (F) Brightfield images of HeLa (E) and SiHa (F) spheroids after treatment with 10 µM 
CPX for 2-8 days. Scale bar: 500 µm. (G) Immunohistochemical stainings of HeLa spheroids that 
were treated with 10 µM CPX for 72 h. A 10x magnification is shown, scale bar: 100 µm.  
 
2.3 CPX induces cell cycle arrest and senescence 
The observed inhibition of cell growth by CPX could be explained by a reduced rate of cell 
proliferation (i.e. through induction of cell cycle arrest) or by an increase of cell death - or by 
a combination of both. To address this question, first, the cell cycle distribution upon CPX 
treatment was assessed with flow cytometry. Analyses of HeLa cells treated with CPX and 
stained with propidium iodide (PI) indicate that CPX induces a cell cycle arrest in G1 phase, 
as seen by the increase of the cells in G1 phase from about 60% to 80% after 24 h 
(Figure 12A). To analyse the cell cycle progression in more detail, EdU incorporation assays 
were performed in HeLa cells. EdU as a thymidine analogue is incorporated in the DNA 
during S phase and can be detected using flow cytometry [183]. One representative 
experiment is shown in Figure 12B. Upon EtOH treatment, 24.1% of the cells are in S phase 
as indicated by the positivity for EdU. G0/G1 and G2/M phase can be distinguished by the PI 
content of the cells. CPX treatment strongly decreases the percentage of cells incorporating 
EdU to virtually 0%, suggesting that the cells do no longer synthesise DNA. In comparison to 
the cell cycle analyses with PI alone, it can now be specified that CPX-treated cells are not 
only arrested in G1 phase but also in S phase. Cells with medium PI content (between G1 and 
G2) but negative for EdU represent S phase arrested cells. The reduction of EdU 
incorporation is significant with a p-value below 0.0001 (Figure 12B).  
In order to test whether the cell cycle arrested cells undergo senescence, 
senescence-associated ß-galactosidase assays (SA-ß-gal assays) were performed. With this 
assay senescent cells are stained blue due to senescence-associated ß-galactosidase activity 
[184]. Figure 12C shows that both HeLa and SiHa cells undergo senescence after treatment 
with CPX for 48 h. SA-ß-gal assays were performed 4 days after release from CPX. The 
concomitant colony formation assays (CFAs) further support the induction of senescence (i.e. 
the induction of an irreversible growth arrest) since substantially fewer colonies grow out 
after release from CPX treatment (Figure 12D).  
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Figure 12: CPX induces cell cycle arrest and senescence. (A) Cell cycle analyses of HeLa cells 
treated with EtOH or 10 µM CPX for the indicated time periods. Fraction of cells in G0/G1, S and 
G2/M are indicated (data for this subfigure was obtained in collaboration with Johanna Ira Blase). (B) 
EdU incorporation in HeLa cells upon EtOH or 10 µM CPX treatment for 48 h. One representative 
image is shown. Statistical analysis of three independent experiments is depicted on the right. 
***=p<0.001. (C) HeLa and SiHa cells were treated with 10 µM CPX for 48 h. After treatment, cells 
were split and cultured in CPX-free medium. The split ratio is indicated for each image. 4 days after 
release SA-ß-gal assays were performed (scale bar: 200 µm). (D) Concomitant CFAs to (C) fixed 11 
days after splitting and release. Scheme of experimental setup below.  
 
A key regulator of senescence is p53 which induces the expression of p21, an inhibitor of cell 
cycle progression [74, 185]. Since CPX represses E6, which is involved in the degradation of 
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p53 [36], it was of great interest to investigate whether p53 is reconstituted upon CPX 
treatment and whether increase of p53 is the cause for the induction of senescence. 
Surprisingly, however, total p53 protein levels are not reconstituted upon CPX treatment, but 
decrease after 48 h and 72 h in HeLa (Figure 13A) and SiHa (Figure 13B) cells.  
Since the activity of p53 can be altered through post-translational modifications, 
phosphorylation of p53 at serine 15 was analysed. On the one hand, phosphorylation of p53 at 
serine 15 stabilises p53 since it impedes interaction with and thus degradation through MDM2 
[186]. On the other hand P-Ser15 of p53 is necessary for the transactivation of p53-responsive 
promoters including the CDKN1A promoter (encoding p21) [187]. Interestingly, CPX induces 
a strong phosphorylation of p53 at serine 15. In HeLa cells (Figure 13A) p53 is continuously 
phosphorylated upon CPX exposure from 24 h to 72 h, whereas in SiHa cells (Figure 13B) 
p53 phosphorylation appears to be transient in that it is detectable after 24 h treatment with 
CPX but not at later points of time. Furthermore, p21 protein levels were analysed in HeLa 
(Figure 13A) and SiHa (Figure 13B) cells and an increase is visible after 24 h CPX exposure 
in both cell lines. After 48 h and 72 h p21 protein levels are decreased. Notably, p21 
downregulation was observed in HeLa despite p53 phosphorylation at serine 15. 
 
Figure 13: CPX induces phosphorylation of p53 at Ser15. (A), (B) HeLa (A) and SiHa (B) cells 
were treated with 10 µM CPX for 24-72 h. P-p53 (Ser15), total p53, p21, E7 and ferritin were 
detected. ß-actin was used as loading control.  
 
Phosphorylation of serine 15 of p53 can occur as a response to DNA damage. To investigate 
whether the CPX-induced increase of P-p53 (Ser15) is linked to DNA damage, CPX-treated 
cells were analysed for histone H2AX phosphorylation (γ-H2AX) - a marker for DNA 
damage [188]. In both HeLa (Figure 14A) and SiHa (Figure 14B) cells a clear increase of 
γ-H2AX can be observed upon CPX treatment, indicating that CPX can induce DNA damage.  
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Figure 14: CPX causes DNA damage. (A), (B) HeLa (A) and SiHa (B) cells were treated with 
10 µM CPX for the indicated time periods. γ-H2AX expression was assessed by immunofluorescence 
(scale bar: 50 µm).  
 
To investigate whether p53 is necessary for the induction of senescence we took advantage of 
a HeLa cell line (HeLa “p53 null”), in which p53 is constantly and efficiently repressed by the 
stable expression of an shRNA targeting TP53 [189]. Notably, CPX can induce senescence in 
HeLa “p53 null” cells as shown by SA-ß-gal assays (Figure 15A). The notion is corroborated 
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by the decreased colony forming capacity as seen in concomitant CFAs (Figure 15B). Alike 
HeLa cells expressing p53 (Figure 12), HeLa “p53 null” cells also arrest in G1 phase as 
indicated by the increase of cells in G1 phase (Figure 15C). Moreover, EdU incorporation in 
HeLa “p53 null” cells was comparably repressed as in HeLa expressing p53 (please compare 
Figure 15D with Figure 12B). Collectively, the data indicate that both cell cycle arrest and the 
induction of senescence by CPX can occur p53-independent.  
Furthermore, the repression of E6 and E7 by CPX is also p53-independent since it can be also 
observed in HeLa “p53 null” cells (Figure 15E). Importantly, neither P-p53 nor p53 were 
detectable upon CPX treatment (Figure 15F) indicating that knockdown of p53 remains 
efficient in HeLa “p53 null” cells under these experimental conditions. 
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Figure 15: Senescence and cell cycle arrest induced by CPX are p53-independent. (A) Senescence 
assays in HeLa “p53 null” cells concomitant to Figure 12. Cells were treated with 10 µM CPX for 
48 h, released and subjected to SA-ß-gal staining 6 days after splitting (scale bar: 200 µm). (B) 
Concomitant CFAs to (A) fixed 11 days after splitting. (C) Cell cycle distribution after 10 µM CPX 
treatment in HeLa “p53 null” cells (the data was obtained in collaboration with Johanna Ira Blase and 
is also depicted in [190]). (D) EdU incorporation after 48 h 10 µM CPX treatment. One exemplary 
experiment is shown. Statistical analyses of three independent experiments are shown at the bottom. 
***=p<0.001. (E) Western blot analyses of HeLa “p53 null” cells treated with 10 µM CPX for 
12-72 h. (F) HeLa “p53 null” and HeLa cells were treated with 10 µM CPX for the indicated time 
periods. Western blot analyses of p53 and P-p53 (Ser15) are depicted. ß-actin served as loading 
control. 
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It was furthermore tested whether HIF-1α is involved in CPX-induced E6/E7 repression, since 
HIF-1α is known to be upregulated by CPX [146]. However, knockdown experiments indicate 
that E6/E7 repression by CPX is independent of HIF-1α, since it can be observed in cells 
efficiently depleted of HIF-1α (Figure 16). HIF-2α would not be expected to be involved in 
E6/E7 repression since it is not expressed under normoxic conditions [39] and iron chelators 
additionally inhibit HIF-2α protein translation due to an IRE in the 5’ UTR of the HIF-2α 
mRNA [118].  
 
Figure 16: E6/E7 repression by CPX is HIF-1α-independent. 
HeLa cells were transfected with shRNA against HIF-1α or control 
vectors shcontr-1 and empty vector (EV). Then cells were treated 
with 10 µM CPX for 48 h. Western blot analyses illustrate HIF-1α, 
E6/E7 and ferritin expression.  
 
 
To investigate whether the senescence induction by CPX is caused by iron deprivation, CPX 
was saturated with either iron or zinc prior to applying it to the cells. Senescence assays in 
HeLa (Figure 17A) and SiHa (Figure 17B) cells revealed that senescence induction by CPX, 
alike CPX-induced repression of E7, can be abrogated by saturating CPX with iron. In 
contrast, zinc cannot prevent the senescence induction by CPX. Concomitant CFAs in HeLa 
(Figure 17C) and SiHa (Figure 17D) cells support the notion that CPX induces senescence 
which can be prevented by the addition of iron. Furthermore, treatment of HeLa cells with 
another iron chelator (DFO) also induced senescence (Figure 17E) and reduced colony 
forming capacity (Figure 17F). Collectively, these data indicate that the pro-senescent effects 
of CPX are a consequence of intracellular iron depletion and that senescence induction might 
be a feature of iron chelators in general. 
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Figure 17: Senescence induction by CPX is caused by iron deprivation. (A), (B) HeLa (A) and 
SiHa (B) cells were treated with 10 µM CPX for 48 h and subjected to SA-ß-gal staining 5 days after 
splitting and release. CPX was complexed with 6.67 µM iron (FeSO4, FAC) or zinc (ZnSO4, ZnCl2) 
prior to treatment. Scale bar: 200 µm. Split ratios are indicated in the image. (C), (D) Concomitant 
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CFAs to (A) and (B), respectively, stained 11 days after splitting. (E) Senescence assays of HeLa cells 
treated for 48 h with 100 µM DFO or 10 µM CPX. EtOH served as solvent control for CPX. After 
treatment, cells were split (ratio indicated in the image) and released in medium without iron chelators. 
Cells were stained 4 days after splitting (scale bar: 200 µm). (F) Concomitant CFAs to (E) stained 12 
days after splitting.  
 
2.4 CPX induces apoptosis 
Whereas anti-proliferative effects of CPX could clearly be demonstrated, some cells appear to 
escape senescence induction and continue to grow in CFAs after release from CPX treatment 
(Figure 12D). One explanation is that the cells that grow in CFAs are more resistant to CPX. 
To address this question HeLa and SiHa cells were treated with CPX. Then the cells that grew 
in CFAs were subjected to a second treatment with CPX. It could be observed that these cells 
are again growth-inhibited with CPX to a similar extent as cells that have not encountered 
CPX treatment before (data not shown). Moreover, several attempts to generate CPX-resistant 
cell lines have failed, suggesting that resistance mechanisms against CPX are very unlikely to 
develop. 
Very interestingly, however, when the exposure of CPX was prolonged from two to five days 
the number of HeLa (Figure 18A) and SiHa (Figure 18B) cells that grow out in CFAs after 
CPX release was reduced to zero. Concomitant senescence assays were performed, but very 
few cells could be detected after CPX treatment and release. This suggests that the 
CPX-induced reduction of colony forming capacity in CFAs is not caused by an increase of 
the total number of senescent cells, but by cell death upon treatment and hence loss of cells. 
The induction of cell death by CPX is attributed to iron deprivation since this phenotype 
could be prevented by iron but not zinc (Figure 18A and B). To investigate whether cell death 
by CPX is mediated by apoptosis, several assays were performed (Figure 18C-F). In live cell 
imaging analyses the activation of caspase 3/7 upon CPX exposure was assessed in HeLa 
cells using the IncuCyte® Caspase-3/7 Green Reagent which couples a binding motif for 
activated caspase 3/7 to a DNA intercalating dye. Upon apoptosis induction, activated caspase 
3/7 cleaves the non-fluorescent reagent and generates a fluorescent dye which binds to the 
DNA. Hence, apoptotic cells emit green fluorescence. The number of apoptotic (green) cells 
was normalised to the cell confluence. Upon CPX treatment, the activation of caspase 3/7 
increases over time suggesting that cells start to undergo apoptosis after 2-3 days 
(Figure 18C). A plateau is reached after 4-5 days indicating that all cells are positive for 
activated caspase 3/7. Further, HeLa cells were stained for the apoptosis marker Annexin V 
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and PI upon 72 h treatment with CPX. In comparison to EtOH treatment, CPX increases the 
fraction of late apoptotic cells (Annexin V and PI positive) from 8.74% to 45.3% 
(Figure 18D). Moreover, also in TUNEL assays a time-dependent increase in apoptosis could 
be observed, as exemplified for SiHa cells (Figure 18E). After 48 h treatment with CPX, the 
cells are still negative for TUNEL, yet a reduction of the number of CPX-treated cells is 
visible in comparison to EtOH-treated cells, reflecting the growth inhibitory effect of CPX. 
After 3 and 4 days, however, the number of cells that undergo apoptosis increases as seen by 
the positive TUNEL staining. Notably, apoptosis induction by CPX is also dose-dependent 
since after 4 d treatment with 2 µM CPX the cells are negative for TUNEL, whereas 10 µM 
CPX induces apoptosis (Figure 18F). (As a side note: analogous results were obtained for 
HeLa cells, but SiHa cells were preferentially used for TUNEL assays since apoptotic HeLa 
cells tend to detach from the culture dish and the extent of apoptosis induction would be 
underestimated in HeLa cells). 
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Figure 18: CPX induces apoptosis. (A), (B) CFAs in HeLa (A) and SiHa (B) cells exposed to 10 µM 
CPX for 5 days. CPX was complexed with 6.67 µM iron (FeSO4, FAC) or zinc (ZnSO4, ZnCl2) prior 
to treatment of the cells. After treatment, cells were split and cultured in CPX-free medium. Cells were 
fixed 10 days after splitting. (C) HeLa cells were treated with 10 µM CPX for 7 days in the presence 
of 5 µM IncuCyte® Caspase-3/7 green reagent for apoptosis detection. Activated caspase 3/7 (green 
count/mm²) was assessed and normalised to the confluence (in percent) of the cells. (D) HeLa cells 
were treated with 10 µM CPX for 72 h and stained with Annexin V and PI. Annexin V
+
/PI
-
 cells 
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represent early apoptotic cells, Annexin V
+
/PI
+
 cells represent late apoptotic cells. (E) TUNEL assays 
of SiHa cells after 10 µM CPX treatment for up to 4 days (scale bar: 50 µm). (F) SiHa cells were 
treated with 2 µM or 10 µM CPX for 4 days and subjected to TUNEL assays (scale bar: 50 µm). 
 
The time-dependent induction of apoptosis was also shown by analyses of PARP cleavage. In 
HeLa cells, PARP cleavage is detected after 24 h treatment with CPX and a strong increase is 
seen after 72 h (Figure 19A). In SiHa cells PARP cleavage is detectable after 72 h of CPX 
exposure (Figure 19B). DFO also induces PARP cleavage in HeLa (Figure 19C) and SiHa 
(Figure 19D) cells, suggesting that the apoptosis induction after prolonged treatment is a 
common feature of iron chelators. It should be noted that the concentration of CPX was ten 
times less than the concentration of DFO, indicating that CPX is more potent to induce 
apoptosis. 
 
Figure 19: CPX induces PARP cleavage. (A), (B) HeLa (A) and SiHa (B) cells were treated with 
10 µM CPX for the indicated time periods. PARP cleavage was assessed using an antibody that 
recognises both full length (uncleaved) PARP (upper band) and the larger fragment (lower band) after 
cleavage. (C), (D) HeLa (C) and SiHa (D) cells were treated with 100 µM DFO for the indicated time 
periods (for HeLa, same image of loading control was used in Figure 8A). ß-actin served as loading 
control. 
 
p53 not only plays a role in senescence but also in apoptosis induction [191]. Thus, HeLa 
“p53 null” and HeLa expressing p53 were analysed for caspase 3/7 activation upon CPX 
treatment. Interestingly, the lack of p53 remarkably delays apoptosis (Figure 20A), suggesting 
that p53 contributes to the regulation of apoptosis by CPX. Furthermore, the strong increase 
of PARP cleavage after 72 h exposure to CPX is not seen in HeLa “p53 null cells” 
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(Figure 20B, compare to Figure 19A), consistent with the finding that apoptosis is induced at 
later points of time. The observation that HeLa “p53 null” cells eventually undergo apoptosis 
upon prolonged CPX treatment (Figure 20A) indicates that CPX-induced apoptosis not 
necessarily depends on p53.  
 
Figure 20: Apoptosis induction by CPX is delayed in HeLa "p53 null" cells. (A) HeLa and HeLa 
“p53 null” cells were treated with 10 µM CPX and 5 µM IncuCyte® Caspase-3/7 green reagent for 
apoptosis detection. Activated caspase 3/7 (green count/mm²) was assessed and normalised to the 
confluence (in percent) of the cells (the data for HeLa cells is also shown in Figure 18C). (B) HeLa 
“p53 null” cells were treated with 10 µM CPX for 12-72 h and analysed for (cleaved) PARP 
expression. ß-actin was used as loading control. 
 
To further corroborate that the delay of CPX-induced apoptosis is caused by the lack of p53, 
the experiment was repeated in a different cellular background using HCT116 colon cancer 
cells. HCT116 p53
-/-
 and HCT116 p21
-/-
 cells were supplied by the lab of Bert Vogelstein 
[192, 193] and, together with parental HCT116 cells, subjected to activated caspase 3/7 
measurement upon CPX treatment. A delay in apoptosis can also be observed in 
HCT116 p53
-/-
 cells compared to parental HCT116 cells (Figure 21). In specific, about 50% 
of parental HCT116 cells were killed after 3 days of CPX treatment, whereas 50% of HCT116 
p53
-/-
 cells were dead after 4 days CPX treatment. Notably, the lack of p21 renders HCT116 
cells more vulnerable to CPX treatment since HCT116 p21
-/-
 cells already start to induce 
apoptosis after only 1 day (Figure 21), suggesting that a lack of p21 accelerates apoptosis 
induction by CPX. Collectively, the data comparing HCT116 and HCT116 p53
-/-
 cells also 
indicate that a lack of p53 delays the apoptotic response towards CPX treatment, yet, 
apoptosis induction by CPX can be p53-independent. 
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Figure 21: The lack of p53 delays 
CPX-induced apoptosis in HCT116 
cells. HCT116, HCT116 p53
-/-
 and 
HCT116 p21
-/- 
cells were treated with 
10 µM CPX and 5 µM IncuCyte® 
Caspase-3/7 green reagent for 
apoptosis detection. Activated caspase 
3/7 (green counts/mm²) was measured 
with the IncuCyte® system and 
normalised to the confluence (in 
percent) of the cells.  
 
2.5 CPX induces mTORC1-independent senescence 
According to Blagosklonny et al. a major player in senescence induction is active mTOR 
signalling ([86], please also refer to 1.7 and to Figure 3). In line with this, senescence 
induction upon E6/E7 inhibition was prevented with the mTOR inhibitor rapamycin [39]. To 
investigate whether mTOR signalling is also necessary for CPX-induced senescence, HeLa 
and SiHa cells were pre-treated with the mTOR inhibitor rapamycin and then treated with 
CPX. After treatment, cells were released from CPX and rapamycin, and subjected to 
senescence assays (Figure 22A, B) and CFAs (Figure 22C, D). As indicated by the induction 
of SA-ß-gal activity (blue cells), CPX is able to induce senescence in the presence of 
rapamycin, suggesting that mTOR signalling might not be required for senescence induction 
by CPX. Concomitant CFAs support that notion, since a comparable amount of colonies grow 
out after CPX treatment in the presence and absence of rapamycin. Rapamycin is considered 
to be a specific inhibitor of mTOR complex 1 (mTORC1) [194], although some studies 
indicate that mTORC2 can be inhibited by prolonged treatment with rapamycin [195]. 
Treatment with rapamycin induced effects on mTORC1 downstream targets S6K and 4E-BP1 
as anticipated from studies by Choo et al. [196] and as previously published by our lab [39]. 
In specific, rapamycin decreases the phosphorylation of S6K, but barely affects 4E-BP1 
phosphorylation (Figure 22E, F). The results indicate that under the experimental conditions, 
mTORC1 signalling is downregulated after 24 h rapamycin treatment and hence mTORC1 
signalling through P-S6K appears to be dispensable for CPX-induced senescence. This is 
remarkable since the anti-senescent activity of rapamycin in HPV-positive cancer cells was 
linked to inhibition of S6K phosphorylation [39]. Interestingly, CPX not only is capable of 
inducing senescence under these conditions, but acts as an mTORC1 inhibitor itself since 
P-S6K is downregulated upon CPX treatment in both cell lines (Figure 22G, H). In contrast to 
rapamycin, CPX additionally strongly decreases the phosphorylation of E4-BP1. 
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Figure 22: CPX induces mTORC1-independent senescence. (A), (B) Senescence assays of 
CPX-treated HeLa (A) and SiHa (B) cells in the presence or absence of rapamycin (Rapa). DMSO was 
used as solvent control for rapamycin. Scale bar: 200 µm, split ratios are displayed in the images. (C), 
(D) Concomitant CFAs to (A) and (B). Right side: scheme of experimental setup for (A)-(D): Cells 
were pre-treated with 50 nM rapamycin for 24 h, then 10 µM CPX was added for another 48 h. After 
treatment, cells were split and cultured in medium without CPX and without rapamycin. (E), (F) HeLa 
(E) and SiHa (F) cells were treated with 50 nM rapamycin for 24 h. (G), (H) Western blot analyses of 
HeLa (G) and SiHa (H) cells that were treated according to (A)-(D). Substrates indicating active 
mTORC1 signalling: P-S6K and P-4E-BP1. Vinculin served as loading control. 
 
The repression of mTORC1 by CPX was subsequently investigated in more detail. HeLa 
(Figure 23A) and SiHa (Figure 23B) cells were treated with CPX for different periods of time 
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and mTORC1 signalling was analysed by western blot. P-S6K and P-4E-BP1 are strongly 
downregulated in both HeLa and SiHa cells after 48 h. Total levels of S6K in SiHa also 
slightly decrease after CPX treatment for 48 h and 72 h. Furthermore, protein levels of 
REDD1 (regulated in development and DNA damage responses 1) were analysed. REDD1 is 
a negative regulator of mTORC1 [197] and is upregulated after 12 h and 24 h CPX treatment 
in HeLa and SiHa cells (Figure 23C and D). After 48 h and 72 h, it is strongly repressed. 
Next, it was investigated whether mTOR repression is a specific feature of CPX or whether it 
can be also achieved upon treatment with another iron chelator. Interestingly, DFO represses 
mTORC1 signalling similar to CPX (Figure 23E, F), suggesting that the repression is a 
feature of iron chelators in general. In both cell lines the strongest repression of P-S6K and 
P-4E-BP1 can be observed after 48 h and 72 h. Alike CPX, DFO reduces the levels of S6K in 
SiHa cells. Furthermore, a slight reduction of S6K is seen in HeLa cells after 72 h. REDD1 is 
upregulated by DFO after 8-24 h and decreased after 48-72 h which mirrors the data obtained 
by CPX. Collectively, these results suggest that iron chelators repress mTORC1 signalling 
which may be linked to the induction of the negative regulator REDD1. However, since 
mTORC1 signalling is not restored upon REDD1 repression it is possible that additional 
factors are involved or that the initial induction of REDD1 expression is sufficient to inhibit 
mTORC1 signalling at later points of time. 
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Figure 23: Iron chelators repress mTORC1 signalling. (A), (B) HeLa (A) and SiHa (B) cells were 
treated with 10 µM CPX for 8-72 h and analysed for the expression of P-S6K and P-4E-BP1. Tubulin 
served as loading control. (C), (D) HeLa (C) and SiHa (D) cells were treated with 10 µM CPX for 
12-72 h and analysed for REDD1 expression (same image of loading control as in Figure 19A and B). 
(E), (F) HeLa (E) and SiHa (F) cells were treated with 100 µM DFO for the indicated time periods. 
Substrates of the mTORC1 pathway and REDD1 were analysed. ß-actin served as loading controls. 
 
2.6 CPX exhibits growth inhibitory effects under hypoxic conditions 
The fact that CPX induces senescence in an mTORC1-independent manner suggests the 
possibility that it could also induce senescence under hypoxic conditions, where mTORC1 
signalling is impaired ([198], see also Figure 3). To this end, HeLa and SiHa cells were 
cultured under hypoxic conditions (1% O2) for 24 h, then CPX was added for another 72 h. 
Western blot analyses of SiHa cells (Figure 24A) show that CPX is active under hypoxic 
conditions since CPX can repress E7 further - in addition to the repression of E7 by hypoxia 
itself. E6 is repressed to the detection limit by hypoxia and thus, it could not be assessed 
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whether CPX represses E6 under hypoxic conditions any further. Ferritin is also repressed by 
CPX at 1% oxygen proving that CPX is active under hypoxia. Furthermore, CFAs of HeLa 
and SiHa cells (Figure 24B) show that upon CPX treatment under hypoxic conditions, there is 
a reduced colony forming capacity after release from CPX treatment and hypoxia (see scheme 
in Figure 24C). However, senescence assays do not show an obvious increase in the absolute 
number of senescent cells after CPX treatment in comparison to EtOH suggesting that the 
growth inhibitory effect seen in CFAs is more likely due to the apoptotic component resulting 
from CPX treatment. In line, SiHa cells subjected to TUNEL assays under hypoxic conditions 
indicate that after 3 days of CPX exposure there is a clear increase in apoptosis and after 5 
and 6 days basically all cells are TUNEL positive (Figure 24D). 
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Figure 24: CPX treatment under hypoxic conditions. (A) SiHa cells were treated with 10 µM CPX 
either for 48 h under normoxic conditions (21% O2) or 72 h under hypoxic conditions (1% O2) after 
24 h pre-incubation at 1% O2. Western blot analyses show HPV16 E6/E7 and ferritin expression. 
ß-actin was used as loading control. (B) CFAs of HeLa and SiHa cells after 10 µM CPX treatment for 
72 h under hypoxic conditions. After treatment, cells were split and released, CFAs were stained 
11 days after splitting. (C) Senescence assays of HeLa and SiHa cells treated as in (B), stained 3 days 
after splitting (ratios are indicated, scale bar: 200 µm). Experimental setup is depicted in the scheme 
below. (D) TUNEL assays of SiHa cells treated with EtOH or 10 µM CPX under hypoxic conditions 
after 3-6 days (scale bar: 50 µm). 
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To summarise, CPX treatment under normoxic conditions results in senescence and apoptosis, 
depending on the duration of the treatment. Under hypoxic conditions, cells do not undergo 
senescence upon CPX exposure but primarily react with induction of apoptosis. 
2.7 CPX cooperates with RT and CT 
Many treatment options in the clinic such as radio- and chemotherapy have limited 
efficiencies in targeting hypoxic regions of the tumour [199]. Since CPX exhibits 
anti-tumourigenic effects under hypoxic conditions it was of great interest to test CPX in 
combination with RT and CT. Figure 25 shows the cooperative effect of CPX with RT and 
CT. HeLa and SiHa cells were irradiated and subsequently treated with CPX for 4 days (top 
panels). In the case of hypoxia, cells were incubated at 1% O2 for 24 h prior to irradiation and 
treatment. CFAs show that γ-irradiation is efficient in inhibiting cell growth under normoxic 
conditions in both HeLa (left upper panels) and SiHa (right upper panels) cells since very few 
colonies grew out after release in comparison to non-irradiated controls. Growth inhibition by 
irradiation was less efficient under hypoxic conditions than under normoxia (in SiHa cells the 
effect is only minor). Notably, however, the combinatorial treatment of RT with CPX reduced 
the number of colonies under both normoxic and, importantly, also under hypoxic conditions, 
indicating that CPX can cooperate with RT at normoxia and hypoxia.  
In the case of CT, two compounds were tested: cisplatin (CDDP, middle panels) and 
etoposide (Eto, bottom panels) which were combined with CPX for 3 and 4 days, 
respectively. The efficiency of CDDP was comparable under 21% and 1% oxygen in HeLa 
cells and the concomitant treatment with CPX reduced colony numbers further under both 
conditions. In SiHa cells, the treatment with CDDP alone was much less efficient under 
hypoxic conditions in comparison to normoxia but a combinatorial treatment with CDDP and 
CPX under hypoxic conditions reduced the number of colonies growing in CFAs. The same 
holds true for etoposide in both HeLa and SiHa cells. Efficient growth inhibition by etoposide 
alone is limited to oxygenated cells. Under hypoxic conditions CPX cooperates with 
etoposide and reduces the colony forming capacity. Concomitant senescence assays show that 
under normoxic conditions CDDP and etoposide induce senescence, whereas irradiation and 
CPX mainly induce apoptosis under the tested conditions since very few cells were present 
after treatment. Furthermore, they show the outgrowth of colonies under hypoxic conditions 
which could be prevented by the combinatorial treatment with CPX. The results of the 
senescence assays are depicted in the master’s thesis of Anja Herrmann [200]. Collectively, 
 51 
 
Results 
the results provide strong evidence that CPX can cooperate with both RT and CT under 
normoxic and hypoxic conditions. 
 
Figure 25: CPX cooperates with RT and CT. HeLa (left panels) and SiHa (right panels) cells were 
treated with 10 µM CPX for 4 days after γ-irradiation with 10 Gy (upper panels). Combinatorial 
treatments of 10 µM CPX with 5 µM CDDP (middle panels) for 3 days and 5 µM etoposide (lower 
panels) for 4 days are shown. All cells were split and released after treatment. CFAs were stained 
11 days after release (data obtained in collaboration with Anja Herrmann and also contained in her 
master’s thesis [200]).  
 
2.8 Proteome analyses after CPX treatment 
To further elucidate the mechanisms behind the anti-proliferative effects of CPX, proteome 
analyses were performed, analysing SiHa cells treated with CPX for 48 h under normoxic 
conditions. Out of almost 6000 detected proteins, 377 proteins were differentially expressed 
according to a threshold defined as an at least two-fold increase or decrease (log2 fold change 
≥ +1.0 or ≤ -1.0) and adjusted p-value smaller than 0.05. Among the significantly regulated 
proteins, 85 proteins are upregulated and 292 proteins are downregulated upon CPX 
treatment. The volcano plot illustrates the distribution of all detected proteins according to the 
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log2 fold change and the adjusted p-value (Figure 26A). It can be noticed that among the 
detected proteins the majority is downregulated upon CPX treatment.  
The significantly regulated proteins were ranked according to their log2 fold change and 
subjected to gene set enrichment analyses (GSEA). Among the top ranked gene sets that are 
positively enriched by CPX treatment, gene sets that are also positively regulated by hypoxia 
were detected (Figure 26B shows one exemplary gene set). GSEA further revealed that gene 
sets related to aging and apoptosis are enriched by CPX treatment, corroborating the 
experimental findings obtained in the present work. Among the gene sets that are negatively 
regulated by CPX is the iron sulphur cluster binding gene set (Figure 26B). Another gene set 
is related to cell cycle transition from G1 into S phase. Interestingly, a gene set which is 
involved in the metabolism of nucleotides was found to be negatively regulated by CPX 
(although with a false discovery rate of 0.308). In this context, it is noteworthy that the RR 
has been described as a target of CPX (please refer to 1.14) and hence, it was aimed to 
investigate the role of RR in senescence and apoptosis induction by CPX under normoxic and 
hypoxic conditions. 
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Figure 26: Proteome analyses of CPX treatment. (A) Proteins differentially regulated in SiHa cells 
after 10 µM CPX treatment for 48 h. Volcano plots were obtained in collaboration with Bianca Kuhn. 
(B) GSEA of data obtained with proteome analysis. Selection of gene sets positively (upper panels) or 
negatively (lower panels) enriched by CPX treatment in SiHa cells. FDR, false discovery rate. 
 
2.9 HU induces senescence, but not apoptosis 
Inhibition of RRM2 is known to induce senescence [163]. This iron-containing subunit of RR 
can be inhibited either by iron chelators or HU which destabilises the tyrosyl radical. To 
investigate whether CPX acts via inhibition of RR, cells were treated with the RR inhibitor 
HU under normoxic and hypoxic conditions and results of senescence and apoptosis assays 
were compared to the results obtained with CPX treatment. Figure 27A-D show that HU 
induces senescence both under normoxic (A) and hypoxic (C) conditions as indicated by the 
increase of SA-ß-gal positive cells (blue staining). Consistently, HU reduces the colony 
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forming capacity in HeLa cells under normoxic (B) and hypoxic (D) conditions supporting 
the notion that HU induces senescence. Furthermore, the senescence induction by HU is (alike 
CPX-induced senescence) mTORC1 independent, since cells undergo senescence in the 
presence of the mTORC1 inhibitor rapamycin as indicated by the positive SA-ß-gal staining 
and the reduction of colonies that grow out after HU treatment (Figure 27E, F). Concomitant 
results were obtained in SiHa cells treated with HU under normoxic and hypoxic conditions 
(Supplementary Figure 1). 
 
Figure 27: HU induces senescence. (A) Senescence assays of HeLa cells after 1 mM HU treatment 
for 48 h under normoxic conditions. After splitting at the indicated ratios, cells were released and 
stained for SA-ß-gal 4 days after splitting (scale bar: 200 µm). (B) Concomitant CFAs to (A), fixed 11 
days after splitting. (C) HeLa cells were cultured under hypoxic conditions for 24 h and then treated 
with 1 mM HU for 96 h. After treatment cells were cultured under normoxic conditions and in 
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medium without HU. SA-ß-gal staining was performed 3 days after splitting (scale bar: 200 µm, split 
ratios indicated). (D) Concomitant CFAs to (C) 13 days after splitting. (E) HeLa cells were treated 
with 50 nM rapamycin for 24 h. Then 1 mM HU was added for 48 h. After treatment, cells were split 
at the indicated ratios and cultured in HU- and rapamycin-free medium. Senescence assays were 
performed 4 days after splitting (scale bar: 200 µm). (F) Concomitant CFAs to (E) were stained 10 
days after splitting. 
 
Furthermore, apoptosis was analysed under normoxic and hypoxic conditions in SiHa cells 
upon HU exposure (Figure 28). Treatment with 1 mM HU for up to 4 days under normoxic 
conditions results in a minor increase of apoptotic cells as indicated by TUNEL stainings 
(Figure 28A). Under hypoxic conditions apoptosis could not be detected with 1 mM HU and 
exposure of up to 6 days (Figure 28B). The data suggests that the growth inhibitory effect of 
HU under normoxic and hypoxic conditions is caused by the induction of senescence, but not 
apoptosis. 
 
Figure 28: Apoptosis assays upon HU treatment. (A) SiHa cells were treated with 1 mM HU under 
normoxic conditions for 3 and 4 days and subjected to TUNEL assays (scale bar: 50 µm). (B) SiHa 
cells were cultured at 1% O2 for 24 h. Then 1 mM HU was added for another 6 days and cells were 
subjected to TUNEL assays (scale bar: 50 µm). 
 
Taken together, these results provide an indication that RR inhibition may be involved in 
CPX-induced senescence under normoxia. Both HU and CPX induce mTORC1-independent 
senescence. Furthermore, HU is a described RR inhibitor [180] and CPX as an iron chelator 
can also inhibit RR [147, 160]. However, experiments pinpointing the mechanism of 
senescence induction by CPX to reduced RR activity need to be performed in the future. 
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Preliminary experiments have been performed using shRNA to silence RRM1, RRM2 and 
RRM2B (encoding for p53R2). No effects on senescence induction could be observed which, 
however, was explained by poor knockdown efficiencies. Furthermore, overexpression of 
RRM2 did not prevent the CPX-induced senescence, as well as supplementing cells with 
deoxynucleosides or deoxynucleotides. Nonetheless, further work appears to be warranted, 
which could include a more efficient downregulation of RR subunits by the CRISPR/Cas 
technology or generation of an iron-independent RR in order to illuminate the role of RR as a 
potential target for mediating the pronounced pro-senescent and pro-apoptotic effects of CPX 
in HPV-positive cancer cells. 
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3. Discussion 
HPV-positive cancer cells are oncogene addicted meaning with respect to their malignant 
phenotype they rely on the constant expression of the two viral oncoproteins E6 and E7 [40]. 
Although E6/E7 are considered to be valuable targets for the treatment of HPV-positive 
cancers, therapeutic approaches directed against E6/E7 have not been promoted to the clinic, 
yet. Furthermore, since HPV-positive cancers reversibly shut down E6/E7 expression under 
hypoxic conditions, E6/E7 targeting therapies may only be effective in oxygenated areas 
where E6/E7 are expressed [39]. In addition, the hypoxic subregions of a tumour likely 
contribute to resistance towards radio- and chemotherapy [50] and may contain reservoir cells 
for tumour recurrence upon reoxygenation [39]. Thus, it is of great interest to find a therapy 
that is able to target both normoxic and hypoxic HPV-positive cancer cells. 
In this dissertation iron chelators were studied on their potential to serve as prospective drugs 
against HPV-positive cancers. An emphasis was placed on the iron chelator CPX, since it 
originally has been developed as an antimycotic drug which can be applied topically on skin 
and mucosa. The study shows for the first time that iron chelators like CPX strongly inhibit 
E6/E7 expression. Moreover, CPX induces cellular senescence and apoptosis under normoxic 
conditions which both are desirable phenotypes for anti-cancer therapy. Importantly, CPX 
also exhibits growth inhibitory effects via the induction of apoptosis under hypoxic 
conditions. Since CPX is active under hypoxic conditions it may not only be promising as a 
single agent for cancer therapy but could also complement CT and RT which are usually less 
efficient under hypoxic conditions.  
3.1 Repression of E6/E7 by iron chelators 
All tested iron chelators (DFO and CPX) strongly reduce both E6/E7 mRNA and E6/E7 
proteins amounts. Hence, the repression of E6 and E7 could occur on several mechanistic 
levels, such as transcriptional control, mRNA stability, mRNA translation and/or protein 
stability.  
E6 and E7 are transcribed from polycistronic mRNAs and transcription of E6/E7 is controlled 
by cis-elements in the upstream regulatory region (URR) of the HPV genome. The URR 
harbours several known transcription factor binding sites (reviewed in [201]). Among these 
factors are some that have previously been associated with iron: AP-1 (activator protein-1) 
and NF-IL6 (nuclear factor for interleukin 6 expression, also known as C/EBPß, 
CCAAT/enhancer binding protein-ß).  
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AP-1 was shown to increase its DNA binding activity upon treatment with DFO [202, 203]. It 
is a key activator of E6/E7 transcription [204]. However, depending on the composition of the 
AP-1 complex, it can also act as a transcriptional repressor of HPV E6/E7 [205]. The AP-1 
complex is a dimer consisting of Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1, Fra-2) 
proteins [206]. It was shown that an increase in c-Fos expression and the concomitant 
decrease in Fra-1 expression matches the progression of cervical lesions [207]. Furthermore, 
Fra-1 expression inversely correlates with malignancy of HPV-associated cervical carcinoma 
[208]. Treatment with an antioxidant can change the composition of the AP-1 complex which 
results in repression of HPV E6/E7 [205]. In specific, c-Jun and JunB preferentially dimerise 
with Fra-1 instead of c-Fos upon treatment which results in the repression of HPV E6/E7. 
Further, it is known that Notch-1 expression in HPV-positive cells can also mediate the 
switch from c-Jun/c-Fos to c-Jun/Fra-1 [209] and, consequently, Notch-1 can repress HPV 
E6/E7 transcription [210]. Interestingly, our proteome analyses have shown that Notch-1 
expression is significantly elevated upon CPX treatment, suggesting that the repression of 
E6/E7 may be regulated through alteration of the AP-1 complex to a repressive state. This 
possibility is currently under investigation.  
NF-IL6 is a repressive transcription factor for HPV16 early gene expression [211]. 
Furthermore, its binding to the promoter of inducible nitric oxide synthase is increased upon 
DFO treatment [212]. Hence, repression of E6/E7 transcription could also possibly be 
mediated by repressive binding of NF-IL6 to the URR which also warrants further 
investigation. 
The reduction of E6/E7 mRNA could also be caused by decreased mRNA stabilities. To this 
end, mRNA stability assays were performed by Anja Herrmann in HeLa cells [200]. It was 
shown that HPV18 E6/E7 mRNA stability is not altered upon CPX treatment. Thus, the 
reduction of E6/E7 mRNA upon iron deprivation is most likely caused by a lower 
transcription rate.  
Translation of iron regulated genes can be mediated by the IRE/IRP system (see 1.9 and 
Figure 5). The repression of E6/E7 was shown to be iron-dependent, since it could be 
observed upon treatment with different iron chelators and since it could be abrogated when 
CPX was complexed with iron prior to treatment. Hence, the question arises whether the 
E6/E7 mRNA contains a 5’ IRE similar to ferritin. However, the search for an IRE anywhere 
in the genome of HPV16 or HPV18 with the IRE search tool SIREs Web Server 2.0 [213] 
was negative, indicating that E6/E7 expression might not be regulated by the IRE/IRP system. 
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Interestingly, E6 protein repression upon iron chelation in HeLa cells appears to occur earlier 
than E7 repression. Since the expression of E6 and E7 is regulated by alternative splicing and 
splicing can be affected e.g. by epidermal growth factor (EGF) [214], it might be possible that 
iron is involved in the switch from E6 to E7 transcripts. Another hypothesis is that E6 and E7 
proteins exhibit different protein stabilities after CPX treatment. Experiments by Anja 
Herrmann demonstrate that CPX reduces the half-lives of 18E6 and 16E6 by a factor of two 
and three, respectively [200]. A reduction of the protein half-life could also be observed for 
16E7 in SiHa but the protein stability of 18E7 in HeLa cells was not affected by CPX. Hence, 
the difference between E6 and E7 repression in HeLa cells could possibly be associated to the 
reduced protein stability of E6 but not E7, rendering E7 more stable than E7. The data also 
indicate that - besides downregulation of the mRNA - reduced protein stabilities contribute to 
the decrease of E6/E7 protein expression. The potential of CPX to affect protein stability is in 
line with a recent report describing that CPX can induce the proteasomal degradation of 
Cdc25A by a thus far uncharacterised mechanism [215].  
Taken together it could be shown that iron chelators strongly repress HPV E6 and E7 
expression. There are only two studies available which specifically investigate the effects of 
iron chelators on HPV-positive cancer cells in vitro [216] and in vivo [217]. Only one of them 
[216] assessed HPV oncogene expression, which, however, was restricted to the analysis of 
E6 expression only and showed no alteration upon DFO treatment. In view of the strong and 
robust E6/E7 repression which was detected in the present study in all investigated 
HPV-positive cancer cell lines, it can only be hypothesised that the exposure to DFO was not 
long enough to affect E6 expression in this previous report. Thus, the presented dissertation is 
the first study to reveal iron chelators as potent E6/E7 inhibitors. The repression likely occurs 
on several levels, including transcriptional repression and decreased protein stabilities.  
3.2 Growth inhibition by CPX 
Another major finding of this dissertation is that CPX exerts its growth inhibitory effects 
through different mechanisms. First, it induces cell cycle arrest in G1 and S phase leading to 
cellular senescence. Furthermore, after prolonged exposure to CPX, cells undergo apoptosis.  
The observed capacity of CPX to inhibit proliferation and induce cell cycle arrest is 
corroborated by the finding that other iron chelators induce similar phenotypic effects in cells 
of other histological backgrounds (reviewed in [218]). Furthermore, the anti-proliferative 
effect of CPX in HPV-positive cells is supported by the previous finding that CPX can inhibit 
cell proliferation in HeLa cells [219]. The cell cycle analyses performed in the present 
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dissertation revealed that HeLa cells arrest in G1 phase after CPX treatment, which is 
supported by two other studies linking CPX-mediated growth inhibition to G1 arrest [220, 
221].The additional EdU incorporation assays performed in the present investigations further 
showed that cells also halt in the S phase, suggesting that CPX not only induces a G1 arrest, 
but also blocks S phase progression. Yoon et al. [222] performed BrdU assays (analogous to 
EdU) in Chang cells, which later were identified as HeLa cells. They demonstrated that DFO 
diminishes BrdU incorporation which corroborates our findings of CPX-induced decrease of 
EdU incorporation. Notably, the anti-proliferative properties of iron chelators observed in 
vitro are also detectable in experimental in vivo models (reviewed in [122]). 
A possible mechanism why cells arrest and induce senescence upon CPX treatment is 
CPX-induced inhibition of RRM2, since RRM2 knockdown has previously been linked to 
senescence [163]. Since both HU and CPX induce senescence, the anti-proliferative effect of 
CPX could be mediated via RRM2-inhibition. RR activity is crucial for DNA synthesis during 
S phase. It is essential that the pool of dNTPs rises in S phase, since the nucleotides present in 
G1 phase only would be sufficient for the replication of a small fraction of the genome [223]. 
The expression of RRM2 is induced during S phase [224] in order to increase dNTP synthesis 
and satisfy the demand. Consequently, inhibition of RR with HU in mammalian cells 
decreases the pool of dNTPs. More specifically dATP, dCTP and dGTP are decreased while 
dTTP levels increase [225]. Hence, upon RR inhibition, DNA replication is limited by the 
pre-existing dNTPs from G1 phase. When the cell is depleted of dNTPs by HU, DNA 
synthesis can no longer be pursued and replication forks arrest which can eventually lead to 
DNA double strand breaks [226, 227]. DNA damage is sensed by a complex checkpoint 
cascade that includes ATM and ATR which eventually induce cell cycle arrest [228].  
If CPX induces cell cycle arrest through the inhibition of RR, a decreased dNTP pool will be 
anticipated. To date it has not been investigated whether CPX diminishes the pool of dNTPs. 
However, other iron chelators were tested in one study [229], showing that roughly two-thirds 
of the tested iron chelators, among them DFO, reduce dATP levels and increase dTTP levels, 
which is similar to the findings for HU. Thus, it may be assumed that CPX as an iron chelator 
could also decrease dNTP levels. Consequences of dNTP depletion are (1) inhibition of DNA 
replication in S phase, (2) cell cycle arrest and (3) the introduction of DNA damage 
(discussed above). All these effects were found by this dissertation to be induced by CPX 
treatment in HPV-positive cancer cells. In specific, EdU incorporation assays indicate that 
replication is stalled, which is accompanied by a cell cycle arrest in G1 and S phase. 
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Furthermore, H2AX is phosphorylated indicating the induction of DNA damage response of 
HPV-positive cancer cells by CPX. This latter finding is corroborated by the response of other 
cell types towards CPX treatment [221] and was also observed for another iron chelator, 
mimosine, which activates the DNA damage response, as indicated by H2AX 
phosphorylation and CHK1 and CHK2 phosphorylation (downstream targets of ATR and 
ATM, respectively) [221]. Another link between CPX treatment and the induction of a DNA 
damage response is provided by a study which revealed that CPX exposure increases the 
phosphorylation of CHK1 as a response to active ATR signalling [230].  
Collectively, these data suggest that CPX induces cell cycle arrest through the inhibition of 
DNA synthesis. Most likely, as a consequence of impaired replication, the DNA damage 
response pathway is activated which may be mediated via ATR and CHK1, and which 
eventually leads to cell cycle arrest. 
Senescence is a response to a plethora of stressors, including replication stress and DNA 
damage [72]. It has been proposed that senescence can also be a consequence of 
oncogene-induced depletion of dNTPs levels which causes DNA damage and finally results in 
oncogene-induced senescence [231, 232]. Interestingly, oncogene-induced senescence could 
be prevented by the addition of exogenous nucleotides. Our results revealed that both CPX 
and DFO induce senescence. To investigate the hypothesis whether dNTP depletion is the 
cause for senescence induction by iron chelators, cells treated with CPX were supplemented 
with either deoxynucleosides or dNTPs. If CPX mediates senescence via RR inhibition and 
subsequent loss of dNTPs, restoration of dNTP levels will impede senescence induction. 
Restoration of dNTP levels can be achieved by the addition of dNTPs or deoxynucleosides, 
which can be converted to deoxynucleotides via scavenger pathways (reviewed in [233]). 
However, both approaches could not prevent senescence induction by CPX. Although 
intracellular dNTP levels were not measured, both deoxynucleosides and dNTPs appeared to 
reach the nucleus of the cells. EdU incorporation assays revealed that in the presence of 
deoxynucleosides or dNTPs, EdU is no longer incorporated. This latter finding suggests that 
both deoxynucleosides and dNTPs compete with EdU and hence are incorporated into the 
DNA rather than EdU due to the higher abundance in comparison to EdU. Furthermore, 
HU-induced senescence could also not be prevented by deoxynucleoside or dNTP 
supplementation. The obtained data suggest, that CPX- and HU-induced senescence might not 
be caused by dNTP depletion or that the addition of deoxynucleosides and dNTPs is not able 
to restore the dNTP pool to an extent that is sufficient to prevent senescence.  
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Interestingly, Aird et al. stated that the addition of exogenous nucleosides was only able to 
prevent oncogene-induced senescence, but not senescence induced by DNA damaging agents 
like etoposide and doxorubicin [232]. Hence, it alternatively could be speculated that CPX 
induces senescence as a consequence of DNA damage independent of the dNTP pool which 
thus cannot be prevented by the addition of nucleotides. 
Nonetheless, the presented results demonstrate that senescence induction by CPX is 
iron-dependent, since it can be efficiently blocked by the addition of iron. As E6/E7 
repression by siRNA rapidly induces senescence [39] and CPX represses E6/E7, the most 
obvious explanation is that CPX induces senescence via the repression of E6 and E7. 
Consistent with this, repression of E6/E7 upon CPX treatment can also be prevented by the 
addition of iron. However, CPX also induces senescence in HPV-negative cells, indicating 
that the senescence induction by CPX can be independent of E6/E7 repression. Intriguingly, 
these data also indicate that HPV-positive tumours may be more sensitive to CPX treatment, 
since CPX additionally represses E6/E7 which is essential for the malignant phenotype of 
these cells. 
A major pathway in senescence induction is the stimulation of p53 and its transcriptional 
target p21. Hence, p53 and p21 protein levels were investigated upon CPX treatment. 
Interestingly, after 48 h CPX exposure, leading to senescence, both p53 and p21 proteins are 
downregulated. The finding also argues against the possibility that CPX-induced senescence 
is primarily induced via E6/E7 repression, since the senescence response in HPV-positive 
cancer cells is linked to the reconstitution of p53 and pRb [234, 235] Moreover, the data 
suggests that p53 and p21 might not be relevant for CPX-induced senescence.  
However, at earlier points of time (24 h) p21 expression is elevated. Furthermore, a drastic 
increase in the phosphorylation of serine 15 of p53 was observed which could increase 
p53- mediated activation of target genes [187] despite a reduction of total p53 levels. Serine 
15 can be phosphorylated by ATM and ATR upon DNA damage [236, 237] and the 
phosphorylation prevents binding to and the degradation of phosphorylated p53 through 
MDM2 [186]. The expression of p21 is increased after 24 h, suggesting that the 
phosphorylation of serine 15 is sufficient to increase p21 transcription, although total p53 
levels are not altered. However, the situation appears to be more complex, since in HeLa cells, 
p21 levels are decreased after 48 h and 72 h CPX treatment although P-p53 (Ser15) levels 
remain upregulated. 
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It might be possible, that the initial elevation of p21 after 24 h CPX treatment is sufficient to 
induce senescence, although p21 is downregulated at later points of time. It was shown that 
p21 expression correlates with the amount of DNA damage [238]. At sublethal doses of DNA 
damaging agents, expression is increased to arrest the cell cycle and allow DNA repair. Upon 
lethal doses, p21 is downregulated to allow apoptosis induction. Since both senescence and 
apoptosis induction was observed upon CPX treatment, depending on the duration, it may be 
possible that CPX mediates senescence and apoptosis through p21 induction. DNA damage-
induced senescence can also be mediated by the p16-Rb pathway, also as a secondary 
pathway when p53/p21-mediated senescence induction failed [239]. Specifically, in the 
absence of p53, DNA damage leads to the induction of senescence through ROS-mediated 
p16 expression [240]. p16 can also be induced as a response to other stress stimuli which then 
involves the p38-MAPK pathway [241]. However, given the fact that p16 is overexpressed in 
HPV-positive cancer cells, but does not induce senescence, it is unlikely that CPX induces 
senescence through p16 in HPV-positive cancer cells.  
Adding another level of complexity, several other pathways have been linked to CPX-induced 
cell cycle arrest and senescence. For instance repression of Wnt signalling is considered as a 
trigger for senescence induction in primary human cells which occurs independently of pRb 
and p53, but involves GSK3ß-mediated phosphorylation of histone chaperones [242]. CPX 
was shown to downregulate Wnt signalling as indicated by decreased expression of ß-catenin 
[151] and Wnt target genes [243]. However, the proteome analyses performed in this 
dissertation revealed that ß-catenin expression, a readout for canonical Wnt signalling, is not 
affected by CPX. Also gene set enrichment analyses remained inconclusive whether Wnt 
signalling is affected by CPX treatment. This issue could be further clarified in future studies, 
e.g. by performing luciferase reporter assays which can detect active Wnt signalling, such as 
the TOPflash/FOPflash [244] assay. 
Another study links CPX-induced cell cycle arrest to the degradation of Cdc25A [230]. 
Cdc25A is a phosphatase involved in removing inhibitory phosphorylations from CDK4, 
CDK6, CDK2 and CDK1 [245-247] and hence regulates the transition from G1 to S and G2 
to M phase. CPX induces phosphorylation and subsequent proteasomal degradation of 
Cdc25A, which then results in the accumulation of inhibitory phosphorylated G1-CDKs 
[230]. Consequently, CPX-treated cells arrest in G1 phase. Interestingly, degradation of 
Cdc25A upon CPX treatment is associated with the activation of ATR and CHK1 as a 
response to CPX-induced DNA damage [230], suggesting that it may be associated with RR 
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inhibition. Notably, expression of Cdc25A has also been linked to HPV E7. In reporter 
assays, expression of E7 induces the Cdc25A promoter [248, 249] whereas inhibition of 
E6/E7 represses the Cdc25A promoter in cervical cancer cells [250]. Thus, CPX-induced 
degradation of Cdc25A may additionally be enhanced by CPX-induced repression of E7 in 
HPV-positive cancer cells which downregulates Cdc25A expression.  
Another candidate for contributing to CPX-induced cell cycle arrest is NDRG1 (N-Myc 
downstream regulated gene 1), since NDRG1 is upregulated upon treatment with CPX [150] 
or other iron chelators [251], and increased expression of NDRG1 induces cell cycle arrest 
[252]. Interestingly, the proteome analyses in SiHa cervical cancer cells performed in the 
present investigation also revealed that NDRG1 levels are elevated more than twofold upon 
CPX treatment. Notably, a previous study has reported that ectopic expression of NDRG1 in 
SiHa cells resulted in cell cycle arrest [253]. Thus, it will be highly interesting to further study 
the role of NDRG1 in the CPX-induced proliferation stop in HPV-positive cancer cells, an 
issue which is currently under investigation in the laboratory. 
3.3 CPX induces mTORC1-independent senescence 
Blagosklonny et al. described a model in which mTOR is indispensable for senescence 
induction [86]. In line with this model, treatment with the mTORC1 inhibitor rapamycin 
prevents the induction of an irreversible growth arrest [254]. More specifically, rapamycin 
renders cells competent to resume proliferation when the senescence-inducing stimulus is 
removed (reversible growth arrest). Despite the notion that mTOR signalling is essential for 
senescence induction, and despite the previous work of our lab showing that impairment of 
mTORC1 signalling is important for the evasion from senescence in HPV-positive cancer 
cells [39], the data obtained in the present investigations provide strong evidence that 
senescence can also be induced when mTORC1 signalling is inhibited.  
Here, it is shown that CPX induces senescence in an mTORC1-indepdendent manner since 
treatment with rapamycin does not prevent CPX-induced senescence. Actually, CPX itself 
also downregulates mTORC1 signalling in HPV-positive cells, a finding which is supported 
by the analyses of other cell models [153, 255]. The results of the present study indicate that 
the mTORC1 inhibition could occur via induction of REDD1 which inhibits mTORC1 
through the TSC1/2 axis [197]. Since REDD1 is a direct target of HIF-1α [256] the 
upregulation of REDD1 could be associated to the stabilisation of HIF-1α which was shown 
to be upregulated upon CPX treatment (Figure 16). An additional mechanism by which CPX 
may mediate mTORC1 inhibition is AMPK, which is activated upon lack of ATP [257]. Since 
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CPX activates AMPK, and CPX-mediated mTORC1 inhibition can be prevented by inhibition 
of AMPK to some extent [255], CPX-induced mTORC1 inhibition could be a consequence of 
CPX-induced depletion of ATP levels. This notion is supported by the finding that iron 
chelators indeed reduce ATP levels [229]. 
Interestingly, CPX was reported to induce phosphorylation of AKT at serine 473 [153] - a 
target of mTORC2 signalling [258] - implicating that CPX activates the mTORC2 signalling 
pathway, possibly through the relief of the negative-feedback loop upon mTORC1 inhibition 
[153]. Preliminary data of our lab suggest that CPX slightly induces AKT phosphorylation at 
serine 473 in HPV-positive cells, supporting that notion. Indeed, mTORC2 has been linked to 
senescence induction, e.g. in endothelial cells where senescence was shown to be mediated 
via mTORC2 and could be inhibited by knockdown of RICTOR (a specific component of 
mTORC2) or treatment with an AKT inhibitor [259]. Consequently, CPX may also contribute 
to senescence induction in HPV-positive cancer cells via mTORC2 activation. In line with 
this finding are preliminary results in our laboratory, showing that KU-0063794 - which 
blocks both mTORC1 and mTORC2 [260] - inhibited CPX-induced AKT Ser473 
phosphorylation and partially prevented CPX-induced senescence. To investigate the question 
whether mTORC2 is necessary for CPX-induced senescence in more detail, further studies on 
the involvement of mTORC1 and mTORC2 are warranted, including the application of 
specific inhibitors of mTORC1/2 or knockdowns of specific mTORC1 and mTORC2 
components such as RAPTOR and RICTOR, respectively. 
mTORC2 signalling is intact under hypoxic conditions as indicated by phosphorylation of 
AKT at serine 473 ([261-263] and Bossler et al., submitted for publication). It would be 
conceivable that if CPX mediates senescence via active mTORC2, senescence will also be 
induced under hypoxic conditions. However, no obvious increase in senescent cells could be 
observed upon CPX-treatment at 1% oxygen in comparison to EtOH-treated cells. The data 
indicate that besides mTORC2 additional mechanisms may be involved in CPX-mediated 
senescence which are impaired under hypoxic conditions. Comparative studies of signalling 
pathways that are associated with senescence but differentially regulated under normoxic and 
hypoxic conditions could give insights in the underlying mechanism of CPX-induced 
senescence which occurs under normoxic conditions but not under hypoxia.  
In this context, it is noteworthy that although both HU and CPX induce 
mTORC1-independent senescence under normoxia, only HU is able to induce senescence also 
under hypoxic conditions. It would be of great interest to elucidate the pathway involved in 
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HU-induced senescence under hypoxia and to investigate whether this pathway is altered 
upon CPX treatment.  
The finding that CPX induces mTORC1-independent senescence may have important 
implications for using it as an anti-cancer drug. Many therapies like RT and CT exert their 
anti-tumourigenic effects by inducing senescence. However, induction of senescence is 
accompanied by the establishment of a SASP in fibroblasts in the tumour (micro)environment 
which can promote tumour growth, invasion, migration and metastasis (reviewed in [264]). 
Importantly, mTORC1 signalling is responsible for the establishment of this pro-tumourigenic 
SASP, since it can be counteracted by rapamycin treatment [90]. In specific, the cited study 
shows that fibroblasts that were induced to senesce by irradiation promote tumour growth in 
vitro through secretion of pro-inflammatory SASP factors. Moreover, these fibroblasts also 
promoted tumour growth in xenografts, which could be substantially reduced by the treatment 
with rapamycin. The fact that CPX not only induces senescence but also inhibits mTORC1 
suggests that CPX may have the advantage over other senescence-inducing therapies that it 
prevents the (mTORC1-dependent) pro-tumourigenic SASP. It thus will be of great interest to 
investigate the composition and biological activities of the CPX-induced SASP and to 
compare it with, for example, the irradiation-induced SASP. These studies would include 
comparative measurements of expression and secretion of typical SASP factors like IL-1a/b, 
IL-6 and IL-8 among others (a list of SASP factors can be found in [264]) and analyses of the 
biological effects of the SASP on the phenotype of HPV-positive cancer cells (e.g. by 
co-culture with senescent fibroblasts or by treatment with conditioned medium). If these 
studies reveal that CPX induces a more favourable SASP than other senescence-inducing 
therapies, CPX could be a very potent anti-tumour drug, not only as a monotherapy, but also 
in combinatorial treatments for example with RT and CT. 
3.4 Apoptosis induction by CPX 
Besides cell cycle inhibition and induction of senescence, CPX exerts anti-tumourigenic 
effects by the induction of apoptosis. The presented data indicate, that the cell death of 
HPV-positive cancer cells upon CPX treatment is mediated by apoptosis, since several 
hallmarks of apoptosis were observed: (1) caspase 3/7 is activated, (2) PARP cleavage occurs, 
(3) cells stain positive for Annexin V and PI and (4) cells stain positive for TUNEL. The 
general potential of CPX to induce apoptosis is further corroborated by several studies in vitro 
(selection: [265-268]) and in vivo [149, 269]. As a possible mechanism, CPX was shown to 
downregulate the anti-apoptotic proteins BCL-XL and survivin [149], which results in the 
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release of cytochrome c from the mitochondria and activation of the caspase cascade which 
initiates apoptosis. The results obtained in this dissertation also indicate that activation of the 
caspase cascade is involved in CPX-induced apoptosis, since caspase 3 and caspase 7 are 
activated upon CPX treatment (Figure 18C) and PARP cleavage occurs (Figure 19). To 
further corroborate the involvement of caspases in CPX-induced apoptosis it would be 
worthwhile to treat cells with CPX in the presence of the pan-caspase inhibitor z-VAD-FMK. 
Indeed, z-VAD-FMK is able to partially prevent CPX-induced apoptosis in human 
rhabdomyosarcoma cells [149].  
However, since z-VAD-FMK could not completely abrogate apoptosis upon CPX treatment 
[149] it is possible that CPX mediates cell death also via additional, caspase-independent 
pathways. A possible scenario of cell death without the involvement of caspases is 
mitochondrial dysfunction, resulting in the loss of the mitochondrial transmembrane potential 
and the release of cytochrome c and components of the respiratory chain [270]. The effect of 
iron chelators on mitochondria is complex. On the one hand, CPX can prevent the 
depolarisation of the mitochondrial membrane upon H2O2 treatment [271]; most likely 
through the anti-oxidative properties of CPX [272]. On the other hand, DFO downregulates 
components of the iron-sulphur clusters of the respiratory chain and thereby inhibits complex 
II activity [273]. The proteome analyses performed in the present dissertation support the 
notion that CPX inhibits the respiratory chain complexes since gene sets of oxidative 
phosphorylation were negatively enriched by CPX treatment. It is further corroborated by the 
finding that CPX can induce a collapse of the mitochondrial membrane potential [274].  
Mechanistically, CPX-mediated apoptosis might also be supported by the inhibition of the 
deoxyhypusine hydroxylase (DOHH). Several studies show that CPX can inhibit this 
iron-dependent enzyme and, subsequently, the maturation of the eukaryotic translation 
initiation factor eIF5A which is hypusinated by DOHH [148, 219, 275]. Unhypusinated 
eIF5A1 is a trigger for the induction of mitochondrial apoptosis in HeLa S3 cells and 
overexpression of (unhypusinated) eIF5A1 results in the loss of mitochondrial transmembrane 
potential, release of cytochrome c and caspase activation [276]. Consistently, Hanauske-Abel 
et al. have linked apoptosis induction by CPX to the inhibition of eIF5A1 hydroxylation 
[274]. They furthermore state that apoptosis induction by CPX is independent of p53 since it 
can also be observed in HPV-positive cells. The latter statement certainly is an 
overinterpretation of their data, since p53 is still detectable in HPV-positive cells. Yet, the 
present dissertation provides experimental evidence that CPX-induced apoptosis in HeLa cells 
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can occur independent of p53 since HeLa “p53 null” cells also undergo apoptosis upon CPX 
treatment, although the process is delayed. p53-independent apoptosis by CPX could 
furthermore be shown in HCT116 cells. The observation that the lack of p21 in HCT116 cells 
(expressing wildtype p53) actually renders these cells more vulnerable to the pro-apoptotic 
effects of CPX treatment is consistent with the notion that p21 is considered to be an inhibitor 
of p53-dependent apoptosis [277].  
An interesting study was performed by Baar et al. [278] who demonstrated that senescent 
cells can be forced to undergo apoptosis. Usually, senescent cells are considered to be 
protected from apoptosis [279]. Baar et al. proposed a model where senescent cells are 
protected from apoptosis by the expression of FOXO4 which sequesters p53 [278]. Inhibition 
of FOXO4 results in the release of p53 from the nucleus and selectively induces apoptosis of 
senescent cells. CPX induces senescence after 48 h treatment (and release in CPX-free 
medium) but also apoptosis upon prolonged CPX treatment in HPV-positive cancer cells. 
Furthermore, in preliminary experiments it could be observed that CPX is able to induce 
apoptosis in irradiated, senescent fibroblasts. Hence, it is conceivable that CPX interferes with 
an anti-apoptotic pathway in senescent cells and thereby induces apoptosis in senescent cells. 
Likely, however, this does not involve FOXO4, since preliminary experiments indicate that 
FOXO4 silencing did not affect CPX-induced apoptosis in HPV-positive cells (not shown). 
In contrast to senescence, apoptosis induction upon CPX treatment can also be observed 
under hypoxic conditions. To investigate whether apoptosis induction of CPX might be 
mediated via RR inhibition, apoptosis was measured upon treatment with the RR inhibitor 
HU. Although some studies demonstrate the apoptosis-inducing effect of HU [280-283], it 
was not observed in SiHa cells, suggesting that CPX-induced apoptosis might not be linked to 
RR inhibition. 
Apoptosis as a consequence of hypoxia can be caused by inhibition of the electron transport 
chain of the mitochondria which leads to the decrease of the mitochondrial membrane 
potential, lack of ATP, activation of BAX/BAK and the release of cytochrome c [284]. Since 
CPX might inhibit the iron-sulphur clusters as observed for DFO [273] it is possible that 
CPX-mediated apoptosis under hypoxic conditions is mediated by targeting the mitochondria. 
Interestingly, the addition of glucose which maintains ATP levels under hypoxia was 
sufficient to prevent hypoxia-induced apoptosis, suggesting that not hypoxia per se, but the 
lack of ATP upon hypoxia triggers apoptosis [285]. Similar observations were made with 
CPX treatment. When cells under normoxia were cultured with excess glucose - for instance 
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in high glucose medium (25 mM instead of 5.5 mM), at low densities or with excess 
medium - CPX-induced apoptosis was remarkably delayed, suggesting that CPX-induced 
apoptosis could also be mediated by the depletion of ATP.  
Another possible mechanism involves ROS, which are elevated under hypoxic conditions 
[54]. Apoptosis under hypoxic conditions is mediated by the activation of caspase 9 in a 
ROS-dependent manner [286]. In the presence of the radical scavenger N-acetylcysteine 
(NAC), hypoxia-induced elevation of ROS and apoptosis can be prevented. The effect of CPX 
on ROS levels is controversially debated.  
Finally, apoptosis under hypoxic conditions can also be mediated via HIF-1α, which can 
induce the expression of pro-apoptotic proteins of the BCL-2 family [287] or stabilise p53 
[288] under hypoxic conditions. Since CPX induces HIF-1α expression under normoxic 
conditions it is possible that apoptosis-induction by CPX is mediated by the upregulation of 
HIF-1α.  
Taken together, CPX is capable of inducing apoptosis independent of oxygen levels. Many 
therapies, such as radio- and chemotherapy, are more efficient in oxygenated than in hypoxic 
tumour regions. Hence, CPX could be used to complement RT and CT. 
3.5 CPX cooperates with RT and CT 
Depending on stage, cervical cancer is usually treated with surgery and/or radiotherapy, either 
alone or in combination with chemotherapy as radiochemotherapy (American Cancer 
Society). The rationale behind combining RT and CT is that the effects of both therapies can 
synergise and enhance the efficacy in comparison to either treatment alone. Furthermore, 
doses can be reduced which decreases toxicities and side effects. RR inhibitors have been 
described to sensitise cells to RT and CT. For instance the RR inhibitor gemcitabine 
synergises with etoposide in vitro [289]. Furthermore, HU treatment in combination with RT 
achieved almost 90% response (partial or complete) in cervical cancer patients in comparison 
to 65% upon RT monotherapy [290]. Since iron chelators can also inhibit RR, it is coherent 
that iron chelators synergise with RT and CT. Indeed, the iron chelator 3-AP is described to 
sensitise cervical cancer cells to RT [291], most likely through RR inhibition-mediated 
impairment of the DNA damage response [292].  
The present data indicate that CPX also cooperates with RT and CT, since it sensitises 
cervical cancer cells to RT as well as etoposide- or CDDP-based CT. The conclusion is 
supported by a study in leukaemia cells, showing that CPX synergises with cytarabine and has 
 72 
 
Discussion 
additive effects with daunorubicin [147]. The cooperative effect of CPX with RT and CT 
could be particularly pronounced in HPV-positive cancer cells, since CPX also represses 
E6/E7 which has been described to synergise with CDDP treatment [293, 294]. 
3.6 Clinical implications 
The systemic application of iron chelators reduces serum iron levels and is hence associated 
with side effects including liver damage [139]. Topical application of CPX only locally 
depletes cells of iron and does not cause systemic toxicities. It is important to note that the 
CPX concentrations tested in this study (10 µM or less) can be achieved in the human skin. 
Kellner et al. show that application of 1% CPX cream on human cadaver skin results in 
concentrations in the millimolar range in the outermost layer of the skin [159]. CPX 
concentrations decrease with penetration depth, but at a depth of 2 cm concentrations above 
7 µM could still be detected [159]. In vivo studies of healthy volunteers show that upon 
topical treatment with 1% CPX cream, concentrations between 340 µM and 8 µM could be 
achieved in the stratum corneum, depending on treatment duration and depth of the skin layer 
analysed [295].  
Nonetheless, it would also be possible to administer CPX orally, since the concentrations used 
in this dissertation can also be achieved by oral gavage of CPX without reaching 
dose-limiting toxicities. For example, in humans up to 2 µM CPX could be reached as serum 
concentrations [157], which were shown by this dissertation to also inhibit tumour growth in 
2D cell culture. 
It should furthermore be noted that due to its widespread use as an antimycotic drug, the 
safety profile of CPX has extensively been studied. Topical administration to skin or vagina is 
devoid of systemic toxicities and mild local reactions only occur in less than 5% of the treated 
patients [141]. Hence, severe side effects of CPX as a topical anti-cancer agent are very 
unlikely. 
A major problem of anti-cancer therapeutics is that cancer cells can develop several resistance 
mechanisms to evade therapy, including drug inactivation or efflux, alterations of drug targets 
and the inhibition of cell death [296]. However, since iron is essential for a plethora of 
biological processes, it is very unlikely that resistance mechanisms against iron chelators 
develop. The finding that is was impossible to generate CPX-resistant HeLa or SiHa cells 
support that notion. It is further corroborated by the fact that not a single case of 
CPX-resistant fungi has been reported yet, although CPX has been used as an antimycotic 
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agent for more than 20 years [141]. Moreover, several attempts to induce CPX-resistance in 
fungi failed [297, 298].  
Taken together, due to the high safety profile of CPX as a topical agent and the fact that 
resistance against CPX is not anticipated, CPX could serve as an agent to treat cancers that are 
located at the skin and mucosa. Furthermore, it seems possible that the concentrations which 
can be achieved with already existing formulations are sufficient to exhibit anti-tumourigenic 
effects. 
3.7 Conclusions 
Collectively, the data reveal that iron chelators are strong repressors of the HPV E6 and E7 
oncogenes. Downregulation of the viral oncogenes is detectable both at the protein and 
mRNA levels. Moreover, CPX treatment induces senescence in HPV-positive cancer cells. 
Both viral oncogene repression and induction of senescence is caused by the depletion of iron 
through CPX, since it can be abrogated by the supplementation of iron. Importantly, CPX 
exhibits anti-tumourigenic effects under both normoxic and hypoxic conditions (Figure 29). 
Under normoxic conditions, CPX induces not only senescence but also apoptosis after 
prolonged treatment. In addition, CPX can also induce apoptosis under hypoxic conditions. 
Thus, CPX may not only be an interesting drug for the treatment of HPV-positive cancers as a 
monotherapy, but also in combination with CT and RT. Xenograft studies are planned to 
further strengthen the encouraging in vitro results. 
 
Figure 29: Anti-tumourigenic effects of 
CPX. Under normoxic conditions, CPX 
strongly represses E6/E7, induces 
senescence and apoptosis. Under hypoxia 
the anti-tumourigenic effects are mediated 
by the induction of apoptosis. Image 
modified from [40]. 
 
 
 
Taken together, CPX strongly represses HPV E6/E7, exhibits pronounced anti-tumourigenic 
effects under normoxic and hypoxic conditions and cooperates with CT/RT. Together with the 
fact that CPX can be applied topically and with its excellent safety profile, CPX appears to be 
a very promising candidate for the treatment of HPV-positive cervical (pre)neoplasias.   
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4. Material and Methods 
4.1 Buffers and solutions 
If not stated otherwise all buffers and solutions were prepared with water. 
CSK-1 lysis buffer 
10 mM PIPES (pH 6.8) 
300 mM NaCl 
1 mM EDTA 
300 mM sucrose 
1 mM MgCl2 
0.5% Triton X-100 
100 µl PhosSTOP phosphatase inhibitor cocktail (Roche Diagnostics, Switzerland), 25 µl 
Pefablock (Merck, Germany) and 10 µl P8340 protease inhibitor cocktail (Sigma-Aldrich, 
USA) were added to 900 µl CSK-1 lysis buffer before use. 
4x loading buffer (reducing) 
8% SDS 
250 mM Tris-HCl (pH 6.8) 
20% ß-mercaptoethanol 
40% glycerol 
PBS 
137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.4 mM KH2PO4 (pH 7.4) 
PBS/T 
0.2% Tween®20 
in PBS 
Senescence assay buffer 
40 mM citric acid 
150 mM NaCl 
2 mM MgCl2 
adjusted to pH 6.0 with Na2HPO4 
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5 mM K3[Fe(CN6)], 5 mM K4[Fe(CN6)] and 1 mg/ml X-gal in DMF were added freshly 
before use. 
Senescence assay fixation buffer 
2% PFA 
0.2% glutaraldehyde 
in PBS 
Towbin transfer buffer pH 8.3 
2.5 mM Tris 
192 mM glycerol 
20% methanol 
Tris-Glycine running buffer 
2.5 mM Tris (pH 8.6) 
19.2 mM glycine 
0.1% SDS 
Colony Formation Assay (CFA) buffer 
12 mM crystal violet 
29 mM NaCl 
3.7% PFA 
22% EtOH 
4.2 Chemicals 
All chemicals were molecular biology grade where possible. All standard reagents for buffers 
and media were supplied by AppliChem (Germany), Applied Biosystems (USA), BD 
Biosciences (Germany), BioRad (USA), Carl Roth GmbH (Germany), Enzo Life Science 
(Germany), Fisher Scientific (USA), GE Healthcare (United Kingdom), Gerbu (Germany), 
Gibco (USA), Invitrogen (USA), Merck (Germany), Promega (USA), Roche Diagnostics 
(Switzerland), Saliter (Germany), Serva (Germany) and Sigma-Aldrich (USA). Manufacturers 
of specific reagents are named in the text. 
4.3 Cell-based assays 
4.3.1. Cell culture 
HeLa and SiHa are HPV18 and HPV16- positive cervical cancer cell lines, respectively. 
HCT116 is a human colon carcinoma line. Cells were cultivated in media according to 
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Table 1, supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 
2 mM L-glutamine. Standard cultivation of cells was performed at 37 °C, 5% CO2 in a 
humidified incubator at 21% O2 (normoxia). For experiments under hypoxic conditions (1% 
O2, 5% CO2), cells were transferred into a hypoxic chamber (InvivO2 400 physiological 
oxygen workstation, Ruskinn Technology Ltd, United Kingdom). For passaging, cells were 
washed with PBS, detached with 0.25% trypsin and resuspended in fresh medium. Cells were 
split twice a week. 
Table 1: Cell lines and corresponding media and supplements (where applicable) 
Cells medium supplements 
HeLa DMEM  
SiHa DMEM  
HeLa “p53 null” DMEM 700 µg/ml G418 
HeLa mCherry H2B DMEM 1 µg/ml puromycin 
SiHa mCherry H2B DMEM 1 µg/ml puromycin 
HCT116 McCoy’s  
HCT116 p53
-/-
 McCoy’s  
HCT116 p21
-/-
 McCoy’s  
In order to assess cell growth via the measurement of cell numbers, HeLa and SiHa cells were 
transduced with the pMOWS hH2B mCherry expression vector which fluorescently labels the 
cell nuclei red. The generated cell lines were called HeLa mCherry H2B and SiHa mCherry 
H2B. Transduction was kindly performed by Dr. Joschka Willemsen (Lab of Dr. Binder, 
DKFZ Heidelberg). HeLa “p53 null” cells were previously described by Hengstermann et al 
[189]. This cell line stably expresses a pSUPER-p53 vector encoding shRNA targeting TP53 
and thereby stably repressing p53. HCT116 p53
-/-
 and HCT116 p21
-/-
 were generated by the 
lab of Vogelstein [192, 193]. 
For experiments, cells were counted using trypan blue and Countess
TM
 Automated Cell 
Counter (Invitrogen, USA) and seeded at the cell numbers given in Table 2 if not stated 
otherwise. 3 ml medium was used for 6 cm dishes and 100 µl/well for 96-well plates. For 
experiments performed under normoxic conditions, the medium was replaced with fresh 
medium before treatment. For experiments under hypoxic conditions, medium was replaced 
before the dishes were put in the hypoxic chamber. After the pre-incubation at 1% O2 for 
24 h, drugs were added directly to the medium. 
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Table 2: Cell numbers seeded for experiments 
 6 cm dish 96-well plate (per well) 
HeLa 5.5x10
5
  
SiHa 4x10
5
  
HeLa “p53 null” 4x10
5
 3000 
HeLa mCherry H2B  4500 
SiHa mCherry H2B  3000 
HCT116  6000 
HCT116 p53
-/-
  6000 
HCT116 p21
-/-
  6000 
4.3.1. Cryopreservation and thawing of cells 
For cryopreservation, cells were trypsinised, pelleted by centrifugation (3 min, 800 x g) and 
resuspended in appropriate medium containing 30% FCS and 10% DMSO. Aliquots were 
transferred into an iso-propanol filled freezing container (Nalgene, Thermo Fisher Scientific, 
USA) and frozen at -80 °C. For long-term storage, cells were transferred to liquid nitrogen. 
For thawing, cells were rapidly warmed to 37 °C in a water bath, resuspended in pre-warmed 
medium and transferred into a new cell culture flask. Medium was changed 24 h later. 
4.3.2. Treatment of cells 
Drugs were prepared as stock solutions and diluted to final concentrations as indicated for 
each individual experiment. Some drugs were prepared freshly before treatment. For solvents 
and concentrations of stock solutions see Table 3. 
Table 3: Compounds used 
compound manufacturer stock solution solvent Remark 
DFO Sigma-Aldrich, USA 100 mM water prepared freshly 
CPX Sigma-Aldrich, USA 100 mM EtOH prepared freshly 
etoposide Enzo Life Science, Germany 5 mM DMSO stored at -20 °C 
rapamycin AdipoGen, USA 50 µM DMSO stored at -20 °C 
CDDP Merck, Germany 3.3 mM 0.9% NaCl stored at RT 
FAC Sigma-Aldrich, USA 100 mM water prepared freshly 
FeSO4 Sigma-Aldrich, USA 100 mM water prepared freshly 
ZnSO4 Sigma-Aldrich, USA 100 mM water stored at 4 °C 
ZnCl2 Sigma-Aldrich, USA 100 mM water stored at 4 °C 
4.3.3. Irradiation of cells 
Cell were seeded in 6 cm dishes and irradiated in a Gammacell® 40 Exactor Low Dose Rate 
Research Irradiator (Best Theratronics) with a Caesium-137 source at a constant rate of 
0.933 Gy/min. To ensure the hypoxic environment, cells were transported from the hypoxia 
station to the irradiator in airtight boxes (Lock&Lock, South Korea).  
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4.3.4. Transfection of pSUPER constructs 
HeLa cells were transfected using the calcium phosphate coprecipitation technique according 
to Chen and Okayama [299]. In short 6 µg of plasmid DNA was mixed with 150 µl 0.25 M 
CaCl2 and 150 µl 2x BES buffer (50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.95). 
After 20 min incubation at RT the transfection mix was added dropwise to the cells and the 
cells were incubated at 35 °C and 3% CO2 for 16-18 h. Then, cells were washed with PBS and 
fresh medium was added. In case of cell treatment, compounds were added approximately 4 h 
after medium change. The pSUPER constructs in Table 4 were used. The pSUPER plasmid 
served as empty vector (EV) control. For HIF-1α knockdown, 3 µg of each respective shRNA 
were used. 
Table 4: pSUPER constructs 
construct target sequence (5’ 3’) 
pSUPERshcontr-1 CAGUCGCGUUUGCGACUGG 
pSUPERshHIF-1α-1 CUAACUGGACACAGUGUGU 
psUPERshHIF-1α-2 CUGAUGACCAGCAACUUGA 
4.3.5. Senescence Assay 
This assay was described by Dimri et al. [184]. In senescent cells a ß-galactosidase activity 
can be detected at pH 6. The so-called senescence-associated ß-galactosidase (SA-ß-gal) has a 
distinct enzymatic activity from the acidic ß-galactosidase which is expressed in all cells and 
detectable at pH 4. SA-ß-gal can be detected using the chromogenic substrate X-gal which 
results in blue staining of senescent cells. After treatment with drugs, cells were usually split 
at the ratio 1:2, 1:5 and 1:10 in 6 cm dishes in medium without drugs and cultivated under 
normoxic conditions. After 3-7 days, cells were washed with PBS, fixed with senescence 
assay fixation buffer for 3 min, washed and stained with senescence assay buffer. After 
16-24 h of incubation at 37 °C, the senescence assay buffer was replaced by PBS and cells 
were stored at 4 °C until further analyses at the microscope. The used microscope is EVOSxl 
Core Cell Imaging System from Life Technologies (USA). Images with 20x magnification 
were acquired. Splits are indicated in the figures. Times between splitting and fixation are 
indicated in the figure legends. 
4.3.6. Colony formation assay (CFA) 
Similar as for the senescence assay, cells were split after treatment usually at ratios of 1:100 
and 1:200, and incubated in drug-free medium under normoxic conditions. After colonies 
have formed (between 10 and 13 days after splitting, indicated in the figure legends), cells 
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were fixed and stained with CFA buffer for 5 min. After washing with water and drying at 
37° C, dishes were scanned with Epson Perfection 4990 Photo scanner (Epson, Japan). 
4.3.7. Cell cycle analysis 
After treatment, cells were washed with PBS and trypsinised. To also include cells that have 
detached from the dish, both medium and wash were collected and joined with the harvested 
cells. After centrifugation (5 min, 100 x g) cells were resuspended in 300 µl cold PBS (in a 
2 ml Eppendorf tube), 900 µl ice-cold 100% EtOH was added and cells were immediately 
vortexed. After incubation at 4 °C overnight, cells were pelleted, resuspended in 925 µl cold 
PBS and stained with 25 µl of 1 mg/ml PI (final concentration 25 µg/ml). 50 µl of 10 mg/ml 
RNase (final concentration 500 µg/ml) was added to degrade RNA. After incubation for 
30 min at RT in the dark, cell cycle distribution could be analysed by flow cytometry at the 
BD LSR Fortessa (BD, Germany) with the BD FACS Diva Software version v8.0.1. 
Detectors were used according to Table 5. Analyses and image generation was done with 
FlowJo version 10. The Dean-Jett-Fox model was used for the distribution and quantification 
of the cells in G0/G1, S and G2/M phase.  
Table 5: Detectors used at BD LSR Fortessa 
Fluorochrome detector dichroic filter bandpass filter 
PI D 600 LP 310/20 
Eterneon-Red 645 Azide (EdU) C - 670/14 
FITC (Annexin V) B 505 LP 530/30 
4.3.1. EdU assay 
Two hours prior to harvesting, 10 µM EdU was added to the cells. Harvesting, fixation and 
staining was performed with the EdU-Flow cytometry 647 Kit from baseclick (Germany) 
according to the manufacturer’s protocol. In short, cells were trypsinised and pelleted via 
centrifugation at 100 x g for 5 min at 4 °C. Cells were resuspended in 300 µl PBS (in a 2 ml 
Eppendorf tube) and 900 µl ice-cold 100% EtOH was added. The tubes were vortexed 
immediately. After incubation overnight or up to one week at -20 °C, cells were washed with 
3 ml PBS, pelleted and resuspended in 100 µl 1x saponin-based permeabilisation and wash 
buffer in PBS. Then, 500 µl click assay cocktail was added and incubated for 30 min at RT in 
the dark. After washing two times with 1.3 ml saponin-based permeabilisation and wash 
buffer the cells were resuspended in 925 µl PBS and 25 µl of 1 mg/ml PI was added (final 
concentration 25 µg/ml). 50 µl of 10 mg/ml RNAse was also added (final concentration: 
500 µg/ml) and cells were incubated for 30 min at RT in the dark. Then, cells were filtered 
through gauze into FACS tubes and analysed at the BD LSR Fortessa (BD, Germany) with 
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the BD FACS Diva Software version v8.0.1. Analyses and image generation was done with 
FlowJo version 10. Detectors were used according to Table 5. 
4.3.1. Proliferation assay 
For real-time analysis of cell proliferation cells were seeded in 96-well plates and analysed 
with the IncuCyte® system. Usually, 4 images per well were acquired every 3-4 hours at a 
magnification of 10x. Analysis was performed with the IncuCyte® S3 2018A software. 
4.3.2. Caspase-3/7 assay 
Cells were seeded in a 96-well plate. 24 h (HeLa) or 48 h (HCT116) after seeding, medium 
was replaced with medium containing 5 µM IncuCyte® Caspase-3/7 Green Reagents for 
Apoptosis (Sartorius, Germany) and the drugs of interest. Images were taken every 3 h at the 
IncuCyte® for approximately 7 days. The Caspase-3/7 Green Reagent couples a recognition 
motif for activated caspase-3/7 to a DNA intercalating dye. The non-fluorescent substrate can 
be cleaved by activated caspase 3/7 and subsequently releases a fluorescent dye that can bind 
to the DNA. Thus, apoptotic cells emit green fluorescence. 
4.3.3. TUNEL assay 
During apoptosis, DNA double strands are cleaved by endonucleases. The 3’-hydroxyl 
termini that are exposed after cleavage can be detected using the terminal deoxynucleotidyl 
transferase dUTPS nick end labelling (TUNEL) assay. Cells were seeded in 6 cm dishes 
containing glass coverslips. At the given points of time, coverslips were removed from the 
dish and fixed in 4% PFA in PBS for 30 min at RT. After washing with PBS coverslips could 
be stored in 70% EtOH at -20 °C for several weeks. Usually coverslips from all points of time 
were gathered and stained together. For staining, coverslips were washed with PBS, 
permeabilised in 0.1% Triton, 0.1% sodium citrate in PBS for 2 min at 4 °C. Then cells were 
washed twice with PBS and stained with the in situ cell death detection kit, fluorescein 
(Roche, Germany). Cells were incubated with 25 µl TUNEL solution (mix: enzyme 
solution:label solution = 1:10) for 1 h at 37 °C in a humidified chamber. Then, cells were 
washed with PBS (2x 10 min) and incubated with DAPI (1 µg/ml, Roche, Germany) for 5 min 
in the dark. After washing with PBS (2x 10 min) the coverslips were dipped into water, then 
100% EtOH and air-dried. The coverslips were then mounted with Vectashield (Vector 
Laboratories Inc., USA) onto microscope slides. Representative images are shown in the 
Figures. Images were acquired using the motorised inverted Zeiss Cell Observer with LED 
module Colibri.2 470 nm for excitation and the 20x / 0.4 LD PlnN Ph2 DICII objective. 
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4.3.4. γ-H2AX staining 
Cells were grown on glass coverslips in 6 cm dishes and removed from the dish at the given 
points of time. Cells were fixed in 4% PFA for 5 min at RT and washed with PBS. Fixed cells 
could be stored in PBS at 4 °C for a couple of days. For staining, cells were permeabilised 
with 0.1% Triton X-100 in PBS for 5 min at RT. Cell were washed and subsequently blocked 
in 5% BSA in PBS containing 0.1% Triton X-100 and 0.3 M glycine for 20 min at RT. Then 
cells were incubated with mouse anti-γH2AX-antibody (P-Ser139 H2AX No. 05-636 from 
Millipore, Germany) in 3% BSA, 0.1% Triton X-100 in PBS at a dilution of 1:100 for 1 h at 
RT in a humidified chamber. After washing four times with PBS, cells were incubated with 
anti-mouse Cy3 (dilution: 1:400, donkey α-mouse, Cy3-conjugate from Pierce Antibodies) 
and DAPI (1 µg/ml) in PBS for 1 h at RT in a humidified chamber. Cells were then washed 
five times with PBS and mounted with Vectashield onto microscope slides. Images were 
acquired using the motorised inverted Zeiss Cell Observer with LED module Colibri.2 
555 nm for excitation and the 40x / 0.75 EC PlnN Ph2 objective. 
4.3.5. Annexin V apoptosis detection 
Both cell culture supernatant and PBS wash were collected to include cells that have detached 
from the dish and joined with the trypsinised cells. After centrifugation (136 x g for 5 min at 
4 °C) staining was performed using the FITC Annexin V Apoptosis detection Kit I from BD 
Pharmingen (USA) according to the manufacturer’s protocol with slight changes. In short, 
after washing two times with ice-cold PBS, cells were counted and resuspended in 
1x Annexin Binding Buffer to reach a concentration of approximately 2x10
6
 cells/ml. Then 
100 µl (= 2x10
5
 cells) were transferred into a new tube and 5 µl FITC Annexin V and 5 µl PI 
were added. After incubation for 15 min at RT in the dark, 400 µl 1x Annexin Binding buffer 
was added, cells were filtered through gauze and analysed at the BD LSR Fortessa (BD, 
Germany) with the BD FACS Diva Software version v8.0.1. Analyses and image generation 
was done with FlowJo version 10. PI single stained cells and Annexin V single stained cells 
were used for compensation. Detectors were used according to Table 5. 
4.3.6. Generation of spheroids 
3D cell spheroids more closely mimic the heterogeneity of a tumour since cells in the outer 
layer of the spheroid have access to nutrients and oxygen, whereas in the core of the spheroid 
waste accumulates and (depending on the size of the spheroid) a hypoxic region forms. To 
generate spheroids 5000 HeLa or SiHa cells were cultivated in 200 µl medium in 96-well low 
attachment U-bottom plates for suspension cells. To further inhibit the cells from attaching to 
 85 
 
Material and Methods 
the plastic, the medium was supplemented with 30% methylcellulose stock solution. For the 
generation of methylcellulose stock solution, 250 ml DMEM (without supplements) was 
heated to 60 °C. Then 6 g methylcellulose powder (sterile) was added and an emulsion 
formed under heavy stirring for 20 min. Then, 250 ml DMEM (without supplements) at RT 
was added followed by FCS, penicillin, streptomycin and L-glutamine at the standard 
concentrations (see paragraph 4.3). During stirring at 4 °C overnight the powder dissolves in 
the medium. To remove any undissolved methylcellulose powder the solution was centrifuged 
for 2 h at 4500 x g and 90% of the supernatant were collected, aliquoted and stored at -20 °C 
for up to one year. If possible, the solution was thawed overnight at 4 °C.  
Using the cultivation in low attachment plates and 30% methylcellulose stock solution, 
spheroids formed after 2-3 days. For treatment of spheroids, 100 µl of medium was removed 
and 100 µl medium with drugs at twice the final concentration was added. 
4.3.7. Histological staining of spheroids 
Spheroids were collected in a 15 ml falcon tube and within minutes gravity pulled them to the 
bottom of the tube. The supernatant was removed and PBS was added. After spheroids settled 
at the bottom, PBS was removed and the spheroids were fixed in 10 ml 4.5% 
phosphate-buffered PFA at 4 °C overnight. Spheroids were briefly washed two times with 
PBS and then incubated in water for 30 min. Dehydration was performed using ascending 
alcohols. In specific, spheroids were incubated for 45-60 min in 10 ml 70% EtOH, then 85% 
EtOH and 100% EtOH. Finally, spheroids were incubated in 10 ml xylene for 45-60 min. For 
embedding, the spheroids in xylene were transferred into a metal base mold. After removing 
xylene, 60 °C hot paraffin was added and the mold incubated at 70 °C until the paraffin 
melted. The paraffin was exchanged trice in order to remove any xylene residue (one 
incubation at 70 °C was performed overnight). Then the paraffin was left to solidify. Sections 
of 2 µm were stained with a BOND-MAX automated IHC/ISH Stainer (Leica Biosystems, 
Germany) in collaboration with Prof. Dr. Mathias Heikenwälder, DKFZ Heidelberg. The 
following primary and secondary antibodies (Table 6 and Table 7) were used. Images were 
acquired with a Leica DM1000 LED microscope (Leica, Germany). 
Table 6: Primary antibodies for IHC 
antibody company no. species dilution BOND epitope retrieval solution 
ferritin H1 
Santa Cruz 
Biotechnology, USA 
#376594 mouse 1:100 1 (citrate-based) (30 min, 95 °C) 
Ki-67 Thermo Scientific, USA RM-9106-S1 rabbit 1:200 2 (EDTA-based) (30 min, 95 °C) 
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Table 7: Secondary antibodies for IHC 
antibody company no. dilution 
α-mouse IgG-HRP Abcam, United Kingdom ab125904 1:500 
α-rabbit IgG-HRP Leica Biosystems, Germany DS9800 1:1 
4.4 Protein-based assays 
4.4.1. Protein extraction 
For extraction of proteins, cells were scraped in 500 µl ice-cold PBS and centrifuged for 
10 sec at 10000 x g. PBS was removed and cells were either subsequently lysed in an 
appropriate amount of lysis buffer or stored at -20 °C. The cells were lysed with CSK-1 lysis 
buffer for 30 min on ice and centrifuged for 5 min at 13000 x g at 4 °C. The supernatant was 
removed and subjected to protein concentration determination via Bradford. 
4.4.2. Protein concentration determination and preparation of samples 
1 µl of protein lysate was added to 1 ml of Bradford solution (1 ml of protein assay dye 
reagent concentrate plus 4 ml water; BioRad, USA). Absorption at 595 nm was measured 
with a photometer (BioPhotometer D30; Eppendorf, Germany) and protein concentration was 
determined using a BSA standard curve of absorptions plotted against known protein 
concentrations. The lysates were adjusted to a desired concentration and 4x protein loading 
buffer was added. After boiling the samples for 5 min at 95 °C, the denatured and reduced 
proteins could be further subjected to western blot analyses or stored at -80 °C.  
4.4.3. SDS-PAGE, western blot and immunodetection of proteins 
Table 8: SDS-PAGE recipe 
components for 2 separation gels (12.5%) for 2 stacking gels (5%) 
H2O 4.5 ml 3.5 ml 
30% acrylamide/bisacrylamide 4.2 ml 830 µl 
0.47 M Tris-HCl (pH 6.7) - 620 µl 
3 M Tris HCl (pH 8.9) 1.2 ml - 
10% SDS 100 µl 50 µl 
10% APS 10 µl 100 µl 
TEMED 50 µl 5 µl 
Gels were cast according to Table 8 between two glass plates and installed into the Xcell 
SureLock
TM
 Mini-Cell Electrophoresis System (Life Technologies) filled with Tris-Glycine 
running buffer. Proteins were separated during gel electrophoresis at 120 V for approximately 
2 h. Then proteins were transferred onto a methanol-activated PVDF membrane using the 
Trans-Blot® SD Semi-Dry Transfer Cell (BioRad, USA). The gel and membrane were 
sandwiched between four sheets of Whatman filter paper soaked with Towbin transfer buffer 
and blotted for 1 h at 20 V. In order to detect several proteins of different sizes from the same 
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membrane, the membrane was cut in horizontal pieces according to the size of the protein of 
interest. Then, membranes were blocked in blocking solution for 1 h at RT. Usually, the 
blocking solution consists of 5% milk powder and 1% BSA in PBS/T. An exception was 
made for p53 phospho (Ser15) detection, for which the membranes were blocked in 5%BSA 
in PBS/T. 
For immodetection of proteins, the membrane stripe was incubated in blocking solution 
containing the primary antibody at the indicated concentrations (Table 9) over night at 4 °C. 
Then, the membrane was washed 3x 10 min with PBS/T, incubated with secondary antibody 
(Table 10) in blocking solution for 1 h at RT and washed for at least 1 h with PBS/T. All 
antibodies were diluted 5% milk powder, 1% BSA in PBS/T (blocking solution), except for 
ß-actin which was diluted in PBS/T and p53 phospho (Ser15) which was diluted in 5% BSA 
in PBS/T. Enhanced chemiluminescence (ECL) was used to detect the proteins. ECL
TM
 Prime 
Western Blotting Detection Reagent (GE Healthcare, United Kingdom) was applied to the 
membrane, incubated for 1 min and then images were acquired with the Fusion SL Detection 
System (Vilber Lourmat, Germany). 
Table 9: Primary anitbodies for immunodetection 
antibody company no. species dilution 
16E6 Arbor Vita Corporation, USA #849 mouse 1:2000 
16E7 
kind gift of Dr. Müller, DKFZ Heidelberg, 
Germany 
NM2 mouse 1:1000 
18E6 Arbor Vita Corporation, USA #399 mouse 1:2000 
18E7 Zentgraf, DKFZ Heidelberg, Germany 
B (28) #47 
31.10-11.11.95 
chicken 1:1000 
ferritin H1 Santa Cruz Biotechnology, USA #376594 mouse 1:1000 
HIF-1α BD Pharmingen, USA #610959 mouse 1:500 
p21 Santa Cruz Biotechnology, USA #397 rabbit 1:500 
P-4E-BP1 Cell Signaling, USA #9451 rabbit 1:1000 
p53 (DO-1) Santa Cruz Biotechnology, USA #126 mouse 1:1000 
p53 phospho (Ser15) Cell Signaling, USA # 9284 rabbit 1:1000 
S6K( p70S6K) Cell Signaling, USA #9202 rabbit 1:1000 
PARP (Asp214) Cell Signaling, USA #9546 mouse 1:1000 
P-S6K (P-p70S6K) Cell Signaling, USA #9234 rabbit 1:1000 
REDD1 Proteintech, USA # 10638-1-AP rabbit 1:2000 
ß-actin Sigma-Aldrich, USA #A2228 mouse 1:50000 
tubulin Calbiochem, Germany #CP06 mouse 1:5000 
vinculin Santa Cruz Biotechnology, USA #73614 mouse 1:4000 
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Table 10: Secondary antibodies for immunodetection 
secondary antibody company no. dilution 
α-chicken IgG-HRP Santa Cruz Biotechnology, USA #2428 1:5000 
α-mouse IgG-HRP Santa Cruz Biotechnology, USA #2005 1:5000 
α-rabbit IgG-HRP Santa Cruz Biotechnology, USA #2004 1:5000 
4.4.4. Proteome analysis (TMT10plex method) 
Proteome analyses were kindly performed by Bianca Kuhn in the lab of Prof. Jeroen 
Krijgsveld (DKFZ, Heidelberg). Upon treatment proteins were labelled using the Thermo 
Fischer Scientific’s tandem mass tags (TMTs). Since the labelling is isobaric the tags all have 
similar weights although they differ in the distribution of heavy and light isotopes which then 
generates a unique reporter. Up to 10 samples could be measured simultaneously with this 
approach (TMT10plex) using liquid chromatography combined with mass spectrometry 
(LC)-MS/MS. A relative quantification of proteins can by determined by measuring the 
intensities of the unique reporters. 
For proteome analyses SiHa cells were seeded in 6 cm dishes according to Table 2 and treated 
with 10 µM CPX for 48 h. Then cells were harvested by scraping in ice-cold PBS, pelleted 
and stored at -80 °C until further processing. 
The following protocol was kindly provided by Bianca J. Kuhn and describes the sample 
preparation and analysis of the proteins: “Cell pellets were suspended in 0.1% (w/v) 
RapiGest-SF (Waters) in 100 mM triethylammonium bicarbonate (TEAB, pH 8). Cell lysis 
and shearing of chromatin was performed in a Bioruptor Pico (Diagenode) in a final volume 
of max. 300 µl, 15-20 cycles of 30’’/30’’ (ON/OFF) at 4 °C. Protein concentration was 
determined by BCA-assay following the manufacturer’s protocol (Thermo Fisher Scientific). 
Prior to protein digestion disulfide bonds were reduced by 5 mM DTT for 30 min at 60 °C 
and subsequently alkylated with 15 mM 2-chloroacetamide for 30 min at RT. Proteolytic 
digestion was performed with trypsin (sequencing grade modified, Promega) in a protease-to-
protein ratio of 1:50 (w/w) overnight at 37 °C, shaking at 700 rpm. Following digestion, 1% 
trifluoroacetic acid was added (pH < 2) to stop digestion and break down RapiGest by 
incubation at 37 °C for 30 min followed by centrifugation at 20000 x g for 10 min. 
Supernatants were transferred to a new tube and dried in a vacuum centrifuge. 
Isobaric labeling of the peptides was performed with 10-plex TMT reagents according to the 
manufacturer’s protocol (Thermo Fisher Scientific). In brief, 10 µg of sample was dissolved 
in 10 µl, 100 mM TEAB, vortexed and incubated for 10 min at RT. TMT10-plex reagents 
(0.8 mg) were dissolved in 41 μl of acetonitrile (ACN, LC-MS grade). 4.1 µL of TMT reagent 
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was combined with sample and incubated for 1 h at RT. The reaction was quenched by adding 
8 μl of 5% hydroxylamine and incubation for 15 min. Labeling efficacy was checked for each 
sample by MS prior to combining equal amounts and drying in a vacuum centrifuge prior to 
fractionation.  
Dried samples were dissolved in 20 mM ammonium formate (pH 10), prior to fractionation 
on a 1200 Infinity HPLC system (Agilent) with a Gemini C18 column (3 µm, 110 Å, 100 × 
1.0 mm; Phenomenex) using a linear 60 min gradient from 0% to 35% (v/v) ACN in 20 mM 
ammonium formate (pH 10) at a flow rate of 0.1 ml/min. Sixty 1-min fractions were collected 
and pooled into twelve fractions, dried and reconstituted in 0.1% formic acid (FA). Fractions 
were injected by an Easy-nLC 1200 nano-UPLC (Thermo Fisher Scientific) onto a trap 
column (Pepmap, 100 μm x 2 cm, C18, 5 μm 100 Å pores) and separated on an analytical 
column (PepMap RSLC 75 μm × 50 cm, nanoViper, C18, 2 µM, 100 Å) by applying a 
multistep gradient (Solvent A: 0.1% FA in water, Solvent B: 0.1% FA, 80% ACN 29.9% 
water) from : 3-50% B over 90 min. Eluting peptides were electro-sprayed by applying 2 kV 
on a 10 µm Picotip coated emitter (New Objective) into an Orbitrap Fusion™ Tribrid™ 
(Thermo Fisher Scientific) mass spectrometer operated in data-dependent mode of acquisition 
using the vendor supplied default settings for synchronous precursor selection (SPS) MS3 
fragmentation [300]. 
The mass spectra were analysed using Proteome Discoverer 2.1.0.81 (Thermo Fisher 
Scientific), using the SEQUEST search engine against UniProtKB/Swiss-Prot databases of 
Homo sapiens (21.06.2018), and human papillomavirus 16 (21.06.2018) proteome databases. 
Search settings: digestion reagent: trypsin, precursor and product ion tolerances were set at 
20 ppm and 0.5 Da, respectively. Carbamidomethylation of cysteine was set as a fixed 
modification, oxidation of methionine as a variable modification. For TMT labels, 
TMT6-plex on lysine and peptide N-termini were set as a static modification. The percolator 
algorithm was used as the false discovery rate (FDR) calculator, and all peptides were filtered 
at a ‘strict’ target FDR level of 0.01. Proteins were tested for differential expression with 
Linear Models for Microarray Data (limma [301], version 3.36.2; R, version 3.5.1). 
Significant events (FDR < 0.05, |log FC| ≥ 1) were identified after adjusting for multiple 
testing according to Benjamini & Hochberg. The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium via the PRIDE [302] partner repository 
with the dataset identifier PXD011095.” (F. Bossler, B. J. Kuhn, T. Günther, S. J. Kraemer, P. 
Khalkar, S. Adrian, C. Lohrey, A. Holzer, M. Shimobayashi, M. Dürst, A. Mayer, F. Rösl, 
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Adam Grundhoff, J. Krijgsveld, K. Hoppe-Seyler, F. Hoppe-Seyler, submitted for 
publication). 
Volcano Plots were generated using GraphPad Prism Software. For gene set enrichment 
analyses the gene set enrichment analysis software GSEA Desktop v3.0 was used. Only genes 
with a p-value less than 0.05 were used. Genes were ranked according to their log2 fold 
change and a preranked GSEA was run against the current molecular signature database 
(MSigDB) gene sets (gene symbols) from 16.04.18 (msigdb.v6.2.symbols.gmt). 
4.5 RNA-based assays 
4.5.1. RNA isolation 
For RNA isolation the column-based PureLink RNA Mini Kit (Invitrogen, USA) was used 
according to the manufacturer’s protocol. In short 600 µl lysis buffer complemented with 
ß-mercaptoethanol (100 µl per 10 ml lysis buffer) was used to lyse cells grown in a 6 cm dish. 
The lysate could either be stored at -80 °C or subjected to further RNA purification. To 
further process the RNA, 600 µl of 70% EtOH was added and the RNA was transferred onto 
the column followed by washing. To remove unwanted DNA the PureLink DNase Set 
(Invitrogen, USA) was applied. For this 80 µl of DNAse I reaction mix (8 µl 10x DNAse I 
Reaction Buffer, 10 µl DNase (~3 U/µl) and 62 µl water) were added to the column and 
incubated for 15 min at RT. After washing, the RNA was eluted in 40-80 µl water. 
4.5.2. Reverse transcription (RT) and quantitative real-time PCR 
(qRT-PCR) 
The ProtoScript® II First Strand cDNA Synthesis Kit (NEB, USA) was used according to the 
manufacturer’s protocol. cDNA was synthesised using 500 ng RNA and oligodT primers. The 
samples were incubated at 42 °C for 1 h, were heated up to 80 °C for 5 min and then cooled 
down to 4 °C. After the addition of 40 µl water, the samples could be used for qRT-PCR or 
stored at -20 °C. 
For qRT-PCR 2 µl of cDNA, 10 µl SYBR® Green PCR master mix (Applied Biosystems, 
USA), 0.4 µl of 5 pM forward and reverse primer (final concentration 0.1 pM each) and 7.2 µl 
water were analysed with a 7300 Real Time PCR System. The PCR cycles are summarised in 
Table 11. Sequences of primers are listed in Table 12. HPV16 and HPV18 E6/E7 primers 
recognise all three transcript classes of HPV16 and HPV18 E6/E7. 
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Table 11: PCR cycles 
 
step 1  
(primer annealing) 
step 2  
(DNA denaturation) 
step 3  
(elongation) 
step 4  
(dissociation) 
no. of cycles 1 1 40 1 
temperature (°C) 50 95 95/60 95/60/95 
time (min) 2:00 10:00 0:15/1:00 0:15/1:00/0:15 
 
Table 12: Primer for qRT-PCR 
primer sequence (5’ 3’) 
HPV16 E6/E7 forward CAATGTTTCAGGACCCACAGG 
HPV16 E6/E7 reverse CTCACGTCGCAGTAACTGTTG 
HPV18 E6/E7 forward ATGCATGGACCTAAGGCAAC 
HPV18 E6/E7 reverse AGGTCGTCTGCTGAGCTTTC 
ß-actin forward GGACTTCGAGCAAGAGATGGC 
ß-actin reverse GCAGTGATCTCCTTCTGCATC 
transferrin receptor 1 forward TGCTGGAGACTTTGGATCGG 
transferrin receptor 1 reverse TATACAACAGTGGGCTGGCA 
Relative quantification was performed using the comparative Ct (2
∆∆Ct
) method [303]. Ct 
values of E6/E7 or TFR1 were normalised to the reference ß-actin. For statistical analysis of 
fold changes, values were transformed logarithmically.  
4.6 Statistical analyses 
SigmaPlot version 12.5 was used to perform statistical tests. For comparison of relative 
mRNA levels upon CPX treatment a One-Sample t-test was performed with the test mean set 
to zero. Shapiro-Wilk was used for normality statistic and the alpha value was set to 0.05. For 
the comparison of EdU incorporation in EtOH- and CPX-treated cells a t-test was performed 
with the same settings. 
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5. Appendix 
Supplementary figure 
 
Supplementary Figure 1: HU induces senescence in SiHa cells. SiHa cells according to Figure 27. 
(A) SiHa cells were treated under normoxic conditions with 1 mM HU for 48 h. SA-ß-gal was stained 
4 days after splitting (scale bar: 200 µm). (B) Concomitant CFAs to (A), 11 days after splitting. (C) 
SiHa cells were cultivated under hypoxic conditions for 24 h. Then cells were treated with 1 mM HU 
for another 96 h under hypoxic conditions. Senescence assays were performed 3 days after splitting 
(scale bar: 200 µm). (D) Concomitant CFAs (13 days after splitting). (E) Senescence assays after HU 
treatment in the presence of rapamycin (24 h pre-incubation with 50 nM rapamycin, then addition of 
1 mM HU for another 48 h). Staining was performed 4 days after splitting (scale bar: 200 µm). (F) 
Concomitant CFAs to (E), 10 days after splitting. 
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Abbreviations 
(d)ATP  (deoxy)adenosine triphosphate 
(d)CTP  (deoxy)cytidine triphosphate 
(d)GTP  (deoxy)guanosine triphosphate 
(d)TTP  (deoxy)thymidine triphosphate 
3-AP   3-aminopyridine-2-carboxaldehyde thiosemicarbazone 
4E-BP1   eukaryotic translation initiation factor 4E binding protein 1 
AMPK  AMP-activated protein kinase 
AP-1   activator protein 1 
APS    ammonium persulfate 
ARF   alternate reading frame 
ARNT   aryl hydrocarbon receptor nuclear translocator 
ATM   ataxia telangiectasia mutated 
ATR   ataxia telangiectasia and Rad3 related 
BAK   Bcl-2 homologous antagonist killer 
BAX   Bcl-2-associated X protein 
BCL-2   B-cell lymphoma 2 
BCL-XL  B-cell lymphoma-extra large 
BSA   bovine serum albumin 
C/EBPß  CCAAT/enhancer binding protein-ß 
Caspase   cysteine-aspartic protease 
Cdc25A  cell division cycle 25 homolog A 
CDDP   cis-diamminedichloridoplatinum(II)/ cisplatin 
CDK    cyclin-dependent kinase 
CDKN1A  cyclin-dependent kinase inhibitor 1 A 
CFA    colony formation assay 
CHK1/2  checkpoint kinase 1/2 
CIN   cervical intraepithelial neoplasia 
CO2    carbon dioxide 
CPX   ciclopirox (olamine) 
CT    chemotherapy 
Ct    cycle threshold 
DAPI    4’,6-diamidino-2-phenylindole 
DFO   deferoxamine 
DMEM   Dulbecco’s minimal essential medium 
DMF    dimethylformanid 
DMSO   dimethyl sulfoxide 
DMT1   divalent metal transporter 1 
DNA    deoxyribonucleic acid 
dNDP   deoxyribonucleoside diphosphates 
dNTP    deoxyribonucleoside triphosphates 
DOHH  deoxyhypusine hydroxylase 
DTT   dithiothreitol 
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e. g.    exempli gratia 
E2F    elongation factor 2 
E6AP    E6-associated protein 
ECL    enhanced chemoluminescence 
EDTA   ethylenediaminetetraacetic acid 
EdU   5-ethynyl-2’-deoxyuridine 
EGF   epidermal growth factor 
eIF5A    eukaryotic initiation factor 5A protein 
et al.    et alii 
Eto   etoposide 
EtOH    ethanol 
FAC    ferric ammonium citrate 
FACS   fluorescence-activated cell sorting 
FCS    fetal calf serum 
FDA    Food and Drug Administration 
FDR   false discovery rate 
Fe
2+
   ferrous iron 
Fe
3+
   ferric irons 
FeSO4   iron(II) sulphate 
FITC    fluorescein isothiocyanate 
FPN1   ferroportin 
Fra   Fos related antigen 
FTH   ferritin heavy chain 
FTL   ferritin light chain 
G418   geniticin 
GSK3ß  glycogen synthase kinase 3 beta 
H2B   histone 2 B 
H2O   water 
H2O2   hydrogen peroxide 
HAMP  hepcidin antimicrobial peptide 
HIF    hypoxia-inducible factor 
HPV    human papillomavirus 
HRP    horseradish peroxidase 
HU   hydroxyurea 
i. e.   id est 
Ig    immunoglobuline 
IL   interleukin 
INK4   inhibitors of CDK4 
IRE    iron responsive element 
IRP    iron regulatory protein 
LC    liquid chromatography 
LIP   labile iron pool 
log2    binary logarithm 
MAPK  mitogen-activated protein kinase 
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MDM2  mouse double minute 2 homolog 
mRNA   messenger RNA 
MS    mass spectrometry 
mTOR   mechanistic/mammalian target of rapamycin 
mTORC1/mTORC2  mTOR complex 1/mTOR complex 2 
NAC   N-acetylcysteine 
NDRG-1  N-myc downstream regulated gene 1 
NF-IL6  nuclear factor for IL-6 expression 
NTBI    non-transferrin bound iron 
O2    oxygen 
ORF    open reading frame 
p53R2   p53 inducible ribonucleotide reductase 
PARP   poly (adenosine diphosphate-ribose) polymerase 
PBS    phosphate-buffered saline 
PCR    polymerase chain reaction 
PFA    paraformaldehyde 
PHD    prolyl hydroxylase domain enzyme 
PI   propidium iodide 
PIPES    piperazine-N,N’-bis(2-ethanesulfonic acid) sodium salt 
pRb    retinoblastoma protein 
PVDF    polyvinylidene difluoride 
qPCR    quantitative real-time polymerase chain reaction 
qRT-PCR   quantitative real-time reverse transcription-polymerase chain reaction 
Rapa   rapamycin 
RAPTOR  regulatory-associated protein of mTOR 
REDD1   protein regulated in development and DNA damage response 1 
RICTOR  rapamycin-insensitive companion of mTOR 
RNA    ribonucleic acid 
RNAse  ribonuclease 
rNDP   ribonucleoside diphosphates 
rNTP    ribonucleoside triphosphates 
ROS    reactive oxygen species 
RR    ribonucleotide reductase 
RRM1/2   ribonucleotide reductase subunit M1/2 
RT    room temperature 
RT   radiotherapy 
RT   reverse transcription 
S6K/p70S6K   p70 S6 kinase 
SASP   senescence-associated secretory phenotype 
SA-ß-gal   senescence-associated ß-galactosidase 
SDS    sodium dodecyl sulphate 
SDS-PAGE   sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Ser   serine 
siRNA   small interfering RNA 
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STEAP   six-transmembrane epithelial antigen of prostate 
TEMED  tetramethylethylenediamine 
TF    transferrin 
TFR   transferrin receptor 
TMT   tandem mass tag 
tris    tris(hydroxymethyl)aminomethane 
TSC   tuberous sclerosis complex 
TUNEL   terminal desoxynucleotidyl transferase dUTP nick end labelling 
URR   upstream regulatory region 
UTR    untranslated region 
VEGF    vascular endothelial growth factor 
VHL   von Hippel-Lindau tumour suppressor 
Wnt   Wingless/Integrated 
X-gal   5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
ZnCl2   zinc chloride 
ZnSO4   zinc sulphate 
z-VAD-FMK  carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone 
γH2AX  phosphorylated histone 2AX (serine 139) 
 
The one-letter code for nucleotides was applied according to declarations by the International 
Union of Pure and Applied Chemistry (IUPAC).  
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Units and prefixes 
%   percent 
°C   degree Celsius 
Å  angstrom 
g   centrifugal acceleration 
g   gram 
h   hour 
l   litre 
M   molar 
m  metre 
min   minute 
sec   second 
U  unit 
V   volt 
symbol prefix factor 
c centi 10
-2
 
m milli 10
-3
 
µ micro 10
-6
 
n nano 10
-9
 
p piko 10
-12
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